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POLICY
EMQN best practice guidelines for the molecular
genetic diagnosis of hereditary hemochromatosis (HH)
Graça Porto*,1,2, Pierre Brissot3, Dorine W Swinkels4, Heinz Zoller5, Outi Kamarainen6, Simon Patton6,
Isabel Alonso1, Michael Morris6,7 and Steve Keeney6,8
Molecular genetic testing for hereditary hemochromatosis (HH) is recognized as a reference test to conﬁrm the diagnosis of
suspected HH or to predict its risk. The vast majority (typically 490%) of patients with clinically characterized HH are
homozygous for the p.C282Y variant in the HFE gene, referred to as HFE-related HH. Since 1996, HFE genotyping was
implemented in diagnostic algorithms for suspected HH, allowing its early diagnosis and prevention. However, the penetrance of
disease in p.C282Y homozygotes is incomplete. Hence, homozygosity for p.C282Y is not sufﬁcient to diagnose HH. Neither is
p.C282Y homozygosity required for diagnosis as other rare forms of HH exist, generally referred to as non-HFE-related HH. These
pose signiﬁcant challenges when deﬁning criteria for referral, testing protocols, interpretation of test results and reporting
practices. We present best practice guidelines for the molecular genetic diagnosis of HH where recommendations are classiﬁed,
as far as possible, according to the level and strength of evidence. For clariﬁcation, the guidelines’ recommendations are
preceded by a detailed description of the methodology and results obtained with a series of actions taken in order to achieve a
wide expert consensus, namely: (i) a survey on the current practices followed by laboratories offering molecular diagnosis of HH;
(ii) a systematic literature search focused on some identiﬁed controversial topics; (iii) an expert Best Practice Workshop
convened to achieve consensus on the practical recommendations included in the guidelines.
European Journal of Human Genetics (2016) 24, 479–495; doi:10.1038/ejhg.2015.128; published online 8 July 2015
AIM AND SCOPE
The aim of the current guideline is to provide recommendations on:
(i) criteria for testing, (ii) strategies for testing and (iii) reporting
results for the molecular genetic testing of hereditary hemochroma-
tosis (HH). It is intended to guide decisions related to genetic testing
and interpretation of test results for clinical biochemists, geneticists,
genetic counselors, physicians, other health-care providers, individuals
with suspected or conﬁrmed HH and their family members.
BAKGROUND
Classiﬁcation and pathophysiology
HH is a term generally used to deﬁne a group of autosomal recessive
genetic disorders characterized by iron accumulation in parenchymal
organs, primarily the liver, which can potentially result in impaired
organ structure and function. In recent years, hepcidin has been
identiﬁed as the key hormone that controls the saturation of plasma
transferrin with iron (transferrin saturation). Hepcidin deﬁciency
causes increased transferrin saturation, which is the unifying feature
and principal biochemical ﬁnding of all forms of HH. Homozygous or
compound heterozygous defects in the hepcidin gene (HAMP) and in
genes that stimulate hepcidin production such as HFE, HJV and TFR2
are therefore associated with hemochromatosis. Ferroportin disease is
not classiﬁed as hemochromatosis because it is classically not
associated with high transferrin saturation (TS) or low hepcidin
concentrations (reviewed in Fleming and Ponka1). It is an autosomal
dominant disorder caused by genetic defects in SLC40A1, which in its
classical form, is associated with loss of its exporting function and
consequent hepatic and splenic iron overload. In some rare cases,
however, iron overload may occur in patients carrying SLC40A1 gene
defects with a gain of its exporting function. In this case of non-
classical ferroportin disease, patients may exhibit a hemochromatosis
phenotype and are classiﬁed as HH.2 A summary of HH classiﬁcation,
nomenclature, pathogenesis and major clinical features is provided in
Table 1.
HFE-related HH
By far the most common, well-deﬁned and prevalent form of HH is
HFE-related HH, associated with homozygosity for the A allele in the
single nucleotide variant rs1800562, NG_008720.2:g.10633G4A;
NM_000410.3:c.845G4A; NP_000401.1:p.Cys282Tyr), most commonly
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referred in the literature as C282Y (p.C282Y according to the
recommended nomenclature). This form of HH is particularly
common in Caucasians where 1 in 200–300 individuals are homo-
zygous for p.C282Y (reviewed in European Association for the Study of
Liver,3 Bacon et al4 and van Bokhoven et al5). The disease’s penetrance is
low, affecting predominantly males between 40 and 60 years of age.
Despite the remarkable genetic homogeneity of HFE-related HH, the
clinical expression is variable, and 75–85% of p.C282Y homozygous
individuals do not develop the disease.2 This low penetrance of the
genotype emphasizes the need to better deﬁne genetic modiﬁers and
environmental factors which contribute to iron overload and to severe
clinical expression in these individuals.
Epidemiology, clinical diagnosis, management and treatment of HH
was recently reviewed and discussed in several published practice
guidelines and reports.3–9 Those guidelines were speciﬁcally directed to
the common HFE-related HH and do not include the rarer non-HFE-
related forms of HH for which there are still sparse clinical and
epidemiological data available, so that their biochemical or clinical
penetrance is still not known.
Rare forms of HH and ferroportin disease
The rare forms of HH (reviewed in Mayr et al,2 Camaschella and
Poggiali,10 and Brissot et al11), generally classiﬁed as Rare Hereditary
Hemochromatosis (http://www.orpha.net/consor/cgi-bin/Disease_-
Search_Simple.php) comprise the non-HFE-related HH forms such
as juvenile hemochromatosis, associated with variants in the hemo-
juvelin (HFE2 or HJV) or hepcidin (HAMP) genes, and hemochroma-
tosis of adult onset resulting from variants in the gene for transferrin
receptor 2 (TFR2). In addition to these ‘non-HFE-associated hemo-
chromatosis’ variants, rare HFE variants in combination with p.C282Y
have been reported12 as well as the homozygous HFE deletion which
is a common cause of HH in Sardinia.13 As discussed above, genetic
defects in ferroportin (SLC40A1) are associated with ferroportin
disease, an autosomal dominant disorder of iron overload not
generally classiﬁed as HH except when associated with gain of function
variants.
Some rare forms of HH, as well as ferroportin disease, are
increasingly found in patients who have been clinically characterized
as HH and that test negative for p.C282Y homozygosity in HFE. They
present with phenotypically proven hepatic iron overload with no
other explanation. They have a much broader geographical distribu-
tion than the classical HFE-related HH, namely in Asian populations
where they may represent the main non-hematological cause of
hereditary iron overload.14–16 This fact has important implications
for practical molecular diagnostic strategies in countries where the
allele frequency of the p.C282Y variant of the HFE gene is low.
In addition to the genes described above, further genes have been
associated with iron overload. A novel variant in the Iron-Responsive
Element motif of the H-ferritin mRNA was described in a Japanese
family affected by dominantly inherited iron overload,17 but the
impact of this variant as a more widespread cause of HH in
other populations is still not known. Furthermore, genes encoding
endogenous regulators of hepcidin expression, such as the bone
morphogenetic protein 6 (BMP6) or the SMAD 6 and 7 proteins
are candidates for non-HFE-related hemochromatosis in humans.18,19
So far, however, there are no described cases of HH associated with
variants in any of these proteins.
Other genetic iron overload disorders unrelated to HH
It is important to note that other genetic causes of severe iron overload
exist, but these should be distinguished from HH because of their
distinct clinical and pathological presentation. These include
iron-loading anemias due to ineffective erythropoiesis (thalassemia
syndromes, hemoglobinopathies, sideroblastic anemias, congenital
dyserythropoietic anemia) or due to hemolysis, defects in iron
acquisition by the erythroid precursors (hypotransferrinemia, defect
in DMT1, aceruloplasminemia (reviewed in Fleming and Ponka1 and
Donker et al20) or repeated blood transfusions. All these disorders
demand a distinct clinical and molecular diagnosis workup that is out
of the scope of the present document.
Clinical presentation and reasons for genetic testing referral
Early symptoms of HH are non-speciﬁc and may include weakness,
lethargy, weight loss and arthralgia. Other suggestive, but also not
speciﬁc, signs of more advanced disease include skin pigmentation,
liver cirrhosis, chondrocalcinosis, arthritis, diabetes, hypogonadism,
hepatocarcinoma or cardiomyopathy. If any of these conditions is
related to HH, they will be necessarily associated with biochemical
evidence of iron overload, namely an increased TS and elevated serum
ferritin. Biochemical disease expression is usually present in
presymptomatic disease stages, where elevated TS is the ﬁrst indicator
of iron overload. Therefore, patients with consistently increased TS
and serum ferritin (SF) in the absence of hematological diseases are
suspected to have HH and should be referred for molecular genetic
testing. HFE genotyping is the ﬁrst step for diagnosis, conﬁrming or
excluding the diagnosis of HFE-related HH. In patients presenting
with phenotypically proven iron overload (ie, with severely increased
liver iron stores demonstrated by biopsy, magnetic resonance imaging
or quantitative phlebotomies) and a negative test for p.C282Y
homozygosity, genetic testing for other HH-related variants is
indicated if other hepatic or hematological causes have been excluded.
This should be requested from referral centers offering expert advice
on iron overload disorders and appropriate molecular diagnosis.
Particular types of non-HFE-related HH have speciﬁc phenotypic
signs that allow a rational approach to genetic testing in patients with
suspected non-HFE HH. Juvenile hemochromatosis (Hemochroma-
tosis type 2) is generally characterized by its early onset and a
particularly severe phenotype.21 Patients with juvenile hemochroma-
tosis typically present before the age of 30 with severe systemic iron
overload, heart failure and hypopituitarism as common clinical
manifestations. TFR2-related HH is clinically similar to HFE-related
HH and may be suspected in any phenotypically proven HH adult
patient, and even younger patients,22 in the absence of HFE p.C282Y
homozygosity.23 A well-documented unexplained classical iron
overload phenotype in a patient found heterozygous for p.C282Y
should raise the suspicion of other rare variants/deletions in HFE.24
The classical ferroportin disease (type A) is characterized by
a dominant mode of transmission and hepatic and spleen iron
overload mainly in Kupffer cells and macrophages (because of ‘loss
of function’ variants) reﬂected by hyperferritinemia with high/normal
or low TS.25 This disease requires a more careful differential diagnosis
with other very common causes of hyperferritinemia such as the
Dysmetabolic Iron Overload Syndrome associated with insulin resis-
tance and liver steatosis.26 The non-classical form of ferroportin
disease (type B), also with an autosomal dominant mode of
transmission, is characterized by additional hepatocellular iron
deposits and high TS (due to ‘gain of function’ variants) and requires
a differential diagnosis with other forms of HH.27
Strategies for enhanced case detection
Because of the unspeciﬁc nature of the reported signs or symptoms,
effective case detection in HH is largely dependent on a strong clinical
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awareness and motivation to request the appropriate biochemical tests
and subsequent genetic testing in suspected cases. The initial approach
to diagnosis in any suspected case is the determination of TS.
Although not absolutely necessary, it is advisable to conﬁrm elevated
TS with a second determination on a fasting specimen.4 It should be
noted that, in spite of being the most widely accepted screening test for
systemic iron overload and a very well-standardized laboratory
parameter, there is no universally deﬁned TS cutoff value to identify
patients eligible for further testing and a variety of cutoff values have
been used in different studies (reviewed in European Association for
the Study of Liver28). A review of studies in several populations using
cutoffs of TS ranging from 45 to 60% was presented in Table 5 of the
2010 EASL Clinical Practice Guidelines for HFE Hemochromatosis28
and the positive predictive value of elevated TS for the detection of p.
C282Y homozygotes was estimated to vary from 4.3 to 21.7%.28
Besides TS, SF is a surrogate of iron stores and hyperferritinemia is
an indicator of iron overload, when inﬂammatory/malignant condi-
tions are excluded. Although SF is a well-standardized laboratory
parameter, there is also no universally accepted reference range.
A review of studies in several populations using cutoffs of SF ranging
from 250 to 428 μg/l in males and from 130 to 302 μg/l in females is
also shown in Table 5 of the 2010 EASL Clinical Practice Guidelines
for HFE Hemochromatosis, showing a positive predictive value for
detecting p.C282Y homozygosity ranging from 1.6 to 17.6%.28 It
should be stressed that SF can be inﬂuenced by local environmental
factors such as the lifestyle habits of the population (particularly
alcohol consumption, weight gain and sedentary lifestyle) or geogra-
phical region.29 Ideally, cutoff values should be always established
according to local values for the upper limit of the reference range.29
If SF is used as a predictor of HH, it should also be noted that it can be
elevated in the absence of increased iron stores in patients with
chronic inﬂammatory conditions, particularly in patients with liver
disease (alcoholic liver disease, chronic viral hepatitis and
non-alcoholic fatty liver disease).4 Studies have shown that patients
with hyperferritinemia are less likely to be p.C282Y homozygotes if
they have abnormal liver transaminase activities,30 this paradox being
explained by the low yields of hemochromatosis screening reported by
some liver clinics. In this context, it should be noted that iron overload
is not the most common cause of an elevated ferritin, and the ﬁnding
of hyperferritinemia without an increased TS is not a criterion for HFE
genetic testing, demanding a different approach for differential
diagnosis.31
When a diagnosis of HFE-related hemochromatosis is established in
a proband, genetic screening of asymptomatic siblings, or other
ﬁrst-degree relatives, is a cost-effective strategy to enhance case
detection and early diagnosis.32,33 Genetic screening of the general
population is not recommended because of the low penetrance of the
disease. Although biochemical evidence of iron overload usually
precedes symptomatic disease, biochemical population screening for
iron overload is also not recommended because large studies have
failed to show its cost-effectiveness.34,35 However, the true prevalence
of symptomatic HH in the general population, in particular in
European populations, is also unknown, which increases the uncer-
tainty of cost-efﬁciency analyses.
METHODOLOGY AND RESULTS
To achieve a wide expert consensus for these guidelines, a drafting
group compiled the evidence to support recommendations, prior to a
wider consultation. In that context, a survey on the current practices
used by laboratories offering molecular diagnosis of HH was
undertaken, as well as a systematic literature search focused on some
identiﬁed controversial topics. Finally, a group of clinicians and
scientists involved in HH diagnostics and iron disorders, supported
by the European Molecular Genetics Quality Network (EMQN), met
on 14–15 May 2014 at a workshop in Porto, Portugal to consider
the collected evidence and to formulate best practice guidelines.
Discussions at the workshop focused on testing criteria and protocols,
interpretation of results and reporting. Consensus guidelines were
established. To comply with current standards for evidence assess-
ment, recommendations have been weighted according to the Grading
of Recommendations Assessment, Development and Evaluation sys-
tem (GRADE).3,36 If the level of published evidence was very low,
decisions were taken based on the experts’ opinion.
Results of the survey on current practices of genetic diagnosis
of HH
In order to assess current practices on the molecular diagnosis of HH,
a survey was conducted by means of a standard questionnaire posted
online (using the SurveyMonkey platform) by the European Molecular
Quality Network (EMQN) from the 20 April to 8 June 2012 and
advertised not only among EMQN members, but also through a
network of clinical and research experts on hemochromatosis and
other iron overload disorders, promoted by the European Federation
of the Associations of Patients with Hemochromatosis (EFAPH). For
the recruitment process, a link to the online survey was emailed out to
all the groups mentioned above asking them to participate. For the
purpose of analysis, a pre-analytical validation was performed with
exclusion of incomplete questionnaires or respondents who did not
declare to perform testing for HFE variants. Descriptive statistical
methods were used to report quantitative data, and content analysis
was used for the replies to the open questions. Validated question-
naires were obtained from a total of 113 participating laboratories
from 26 different countries (Australia, Austria, Belgium, Canada,
Cyprus, Czech Republic, Estonia, France, Germany, Greece, Hungary,
India, Ireland, Israel, Italy, Latvia, Netherlands, Norway, Poland,
Portugal, Slovakia, South Africa, Spain, Sweden, Switzerland and
United Kingdom). The vast majority of responding laboratories were
Clinical Diagnostic Laboratories (89%), 75% of these were members
of the EMQN and 10% participated in other Quality Control schemes
either International Quality Networks (UKNEQAS, Equalis) or local
External Quality Control. A small proportion of respondents (4%)
represented research laboratories and 7% self-reported as Reference
Centers. Participants routinely perform HFE genotyping either at a
local (36%), and/or regional (49%), and/or national (44%) and/or
international (13%) levels. The average volume of requests in the
majority of laboratories (52%) is more than 200 per year, in half of
these being reported a volume of more than 500 requests per year. In
addition to standard p.C282Y/p.H63D HFE genotyping, 22% (n= 25)
of responding laboratories are also offering full gene sequencing for
HFE and the other iron genes required for the diagnosis of non-HFE-
related HH. Most of the laboratories offering these tests receive
requests at a national (72%) or international (28%) level. Some of the
laboratories (n= 10) reported to test for non-HFE HH an average of
more than 20 tests/year, two of them receiving more than 100 or 200
requests/year (respectively, in UK and France). The remaining
reported a volume of 6–20 (n= 10) or 1–5 (n= 5) tests/year.
Current practices on ‘criteria for testing’
The majority of participants in the survey reported that HFE
genotyping is mainly requested for diagnosis of a suspected index
case (ranging from 50 to 75% of requests) and the number of requests
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for predictive (asymptomatic) or carrier testing varies from less than
10 to 50% of all requested tests. The majority of the participating
laboratories do not have speciﬁc prerequisites for HFE genotyping
indicated in the referral form, accepting for testing all requests with a
valid clinical referral. Some laboratories (27%) provide in their referral
forms speciﬁc testing prerequisites which are established either at local
(43%), regional (23%) or national (43%) levels. Regarding the practice
of testing for non-HFE-related HH, the majority (64%) of the
laboratories offering these tests reported to have deﬁned strategies
for the selection and order of tests, but only a few (n= 6) refer to
published guidelines available on their national reference websites.
Prerequisites indicated in the referral form are used in some
laboratories (n= 9) which were either established locally (n= 3) or
at a national level (n= 6).
In general, referrals for testing that do not meet the established
criteria are accepted or not according to different local policies. When
asked about their practice regarding the follow-up of missing clinical
prerequisites, the majority of respondents report contacts with the
referring clinician either by telephone or E-mail (45%) or sending
back the referral form asking for the requisites (36%). The remaining
respondents declared that they searched for information on other
available databases (9%), simply accepted the requests (9%) or added
comments on the report form (18%).
When asked about the number of HH cases identiﬁed with p.C282Y
homozygosity, one-third of respondents (33%) reported a detection
rate of less than 5% and only a minority (13%) reported a detection
rate superior to 20%. The majority (54%) reported a detection rate
between 5 and 20%. This rate is similar to the reported prevalence of
p.C282Y homozygosity among patients presenting with elevated TS in
several primary health-care surveys.28 No signiﬁcant differences were
found in terms of detection rates between laboratories who established
prerequisites in the referral forms and those who do not have written
prerequisites, suggesting that the practice of using prerequisites does
not necessarily increase efﬁciency. Owing to its rarity and complexity,
efﬁcacy regarding the diagnosis of non-HFE-related HH was not
addressed in this survey.
Current practice on ‘methods and testing strategies’
Methods used for HFE testing. All the laboratories responding to this
survey routinely screen for the HFE variants p.C282Y and
p.H63D, although some of them (12%) report to have a policy of
testing for p.H63D only in the situation of clinically affected patients
with a previous result showing p.C282Y heterozygosity. In addition,
64% of respondents also test routinely for the p.S65C variant, some of
them reporting that the test is performed occasionally and only on
speciﬁc demands. A minority of laboratories (6%) reported to also
routinely test for other genetic variants included in commercially
sourced kits.
A large number of different methods are used by laboratories. The
four methodological approaches most frequently reported were:
real-time PCR (41%), PCR and RFLP (16%), PCR and reverse
hybridization (14%), and direct sequencing (11%). In addition, other
less commonly used (4.5–5.5%) include: allele-speciﬁc PCR, PCR
and high-resolution melting or single-strand conformational poly-
morphism, pyrosequencing and single base extension. According to
this survey, allelic discrimination real-time PCR was the most
commonly described method for HFE genotyping.
About the need to test for p.H63D for the diagnosis of HFE-related
HH. When questioned about the ‘real need’ and implications of
testing for p.H63D, no consensual opinions were obtained among
respondents. Some respondents declared serious doubts as to whether
they should or should not test for p.H63D (16.7%), whereas others
declared unambiguously that there is no need to test for p.H63D
(19.4%), the most common arguments being that it is not clinically
relevant, it has a high frequency in the normal population with
uncertain implications, or that results may raise anxiety unnecessarily.
The fact that they go on offering this test is, in many cases, explained
by the pressure of requesting clinicians. The majority of laboratories
(48.6%), however, still considered that testing for p.H63D is needed
and/or important, although some of them stressed the importance of a
careful wording on reports, which should be put in context,
particularly in the absence of p.C282Y. The most consistent justiﬁca-
tion for p.H63D testing was the increased risk of iron overload in
p.C282Y/p.H63D compound heterozygotes, a minority also admitting
a risk for p.H63D homozygotes. Some pointed to the importance of
giving lifestyle recommendations in these cases.
Methods used for non-HFE-related HH testing. A total of 25 labora-
tories reported to perform full gene sequencing for the diagnosis of
non-HFE-related HH, the majority of these (52%) offering a panel of
tests for HJV, HAMP, TFR2, SLC40A1 (FPN) and HFE-whole gene.
Some laboratories (24%) also offer testing for FTH1 (for hyper-
ferritinemia), and two of the responding laboratories perform a more
complete panel of tests for other iron overload-related genes adding
5’UTRFTL (for hyperferritinemia), TF (for hypotransferrinemia),
SLC11A2 (for anemia and iron overload), CP (for aceruloplasminemia)
and BMP6 (so far not associated to human HH). The most common
method used is direct DNA sequencing of the coding regions of
selected genes, some laboratories reporting other methods such as
single-strand conformation polymorphism analysis followed by direct
sequencing of the detected variants and next-generation sequencing
(NGS)-based approaches. Multiplex ligation-dependent probe ampli-
ﬁcation has been used in cases where a large gene deletion is suspected.
Current practices on ‘reporting’
The reporting of HFE genotyping results is generally performed by
standard pre-deﬁned templates, most commonly (63%) adapted
according to speciﬁc reasons for referral. The reporting models and
interpretative comments included are usually based on established
guidelines, some laboratories referring to more general guidelines for
genetic testing37–41 but the majority referring to speciﬁc HH guidelines
established either at a national level42–46 or from other published
clinical4,6–9,28 or molecular diagnosis guidelines.47 The majority of
respondents (69%) recommend or suggest predictive/carrier testing
for ﬁrst-degree relatives of detected cases, the majority of these (88%)
speciﬁcally recommending genetic counselling for that purpose.
Among respondents who recommend predictive/carrier testing to
relatives of patients with HFE variants, 16% recommend it only for
ﬁrst-degree relatives of p.C282Y homozygous patients and 57% also
recommend for relatives of p.C282Y heterozygous carriers. In addi-
tion, 28% of the respondents also recommended predictive/carrier
testing to relatives of patients carrying any allele variant combination,
including p.H63D and sometimes p.S65C. About one-third of
respondents (31%) do not recommend in their reports predictive/
carrier testing of relatives of patients with identiﬁed HFE variants.
Current practices on testing minors and value of risk assessment by
testing spouses
When questioned about their policy regarding testing of minors for
HFE-related HH, the majority of respondents (81%) declared to have
a general policy of not testing minors (recommending postponement
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of the genetic test until the subject has reached the age of legal
consent) or testing ‘young’ subjects (not younger than 16 years) as
long as they understand the meaning and implications of the test.
Exceptions to the rule were rare cases referred for diagnosis when
there is a clear clinical indication, in conditions of altered iron status
or evidence of liver disease, and when requested by a specialist (clinical
hematologist or clinical geneticist). The remaining 19% of respondents
declared to test samples from minors whenever requested, deferring
responsibility to the requesting physician and written consent from the
parents. When questioned about the value of offering testing to
spouses to assess risks in offspring, opinions were divided. Opinions
ranged from the total rejection, considering it useless or nonsense, to
the acceptance as an important testing strategy. Arguments used in
favor were mainly as a question of cost-effectiveness, because ‘testing
one spouse is cheaper than testing all the children’ and the possibility of
reassurance to offspring if the spouse does not carry p.C282Y, avoiding
further follow-up arrangements. Some respondents also referred to
satisfying couples who actively seek genetic advice and ask for that test,
and others to the importance of having extended pedigree information
for phenotype interpretation. Arguments against testing spouses
included the inappropriate waste of resources because it is a late-
onset disease and offspring can be offered advice at the appropriate
time; the problems raised by false paternity ﬁndings; and variable
penetrance of the p.C282Y/p.C282Y and p.C282Y/p.H63D genotypes,
making it difﬁcult to predict outcomes for offspring who therefore
should be monitored.
Results of a systematic literature search on controversial topics
The expert team drafted a document that served as the discussion basis
for the ﬁnal guidelines. For most issues addressed, the quality of
evidence and strength of recommendations had been already assessed
elsewhere9,28 according to the system developed by the Grading
of Recommendations Assessment, Development and Evaluation (short
GRADE) Working Group (http://www.gradeworkinggroup.org/index.htm).
For consistency, those scores were used in this guidelines document
accordingly. For some controversial topics, however, we performed a
systemic review of the literature. These topics were: (i) The clinical
value of testing for p.H63D; (ii) Role, efﬁcacy and efﬁciency of cascade
screening; and (iii) Follow-up of unaffected p.C282Y homozygotes
and p.C282Y/p.H63D compound heterozygotes. For the systematic
review, research questions were formulated for each topic. For each
speciﬁc question, search terms were phrased as PICO (Patient,
Intervention, Control and Outcome) that guided the searches in both
MEDLINE and EMBASE using Medical Subject Headings (MESH)
and free text words. Searches were limited to those written in English,
but were not restricted to date.
The clinical value of testing for p.H63D
This was a pending question since the publication of the previous
guidelines for the molecular genetic diagnosis of Type I (HFE-related)
HH29 where the authors raised the question of an eventual call for an
‘iron overload’ genetic screen as opposed to an HFE genetic screen. As
evidenced by the present survey results concerning the question about
testing for p.H63D, there is still much confusion among clinicians and
laboratory scientists regarding the use of HFE variants (particularly p.
H63D) as disease susceptibility markers.
In order to determine the diagnostic utility of p.H63D testing, a
systematic review of the literature was performed. Search terms
according to the following PICO were phrased: Patients (P) were
individuals with hemochromatosis or patients with iron overload.
Intervention (I) was genotyping of the p.H63D variant of the HFE
gene. Controls (C) were newborns or population based screening and
Outcome (O) was the report of genotype frequency. With this search
strategy, 931 references were retrieved. From these, 33 studies were
selected as case–control studies where the hemochromatosis case
deﬁnition was considered appropriate. In addition, 37 population-
based screening studies were selected.
The association with hemochromatosis of the p.H63D variant
in HFE (rs1799945, NG_008720.2:g.8671C4G; NM_000410.3:
c.187C4G; NP_000401.1:p.His63Asp) was in question since its ﬁrst
description.48 Subsequent case–control studies have reported a median
p.C282Y/p.H63D compound heterozygous genotype frequency
among clinically characterized hemochromatosis cohorts of 4.6%
(0–21.7%),48–78 which is signiﬁcantly higher than the compound
heterozygote frequency of 1.7% (0–7.7%) reported in screening
studies.60,63,79–109 Although this observation suggests that compound
heterozygosity is associated with hemochromatosis, longitudinal
studies have shown that the risk of disease progression is low in
compound heterozygotes identiﬁed by screening.110 A more recent
report of the evolution of iron indices in 180 compound heterozygotes
for p.C282Y and p.H63D identiﬁed in the HealthIron study111
concluded that in these, the mean iron indices do not change during
middle age in males but SF increases in females. Although maintaining
elevated iron indices during middle age, documented iron overload-
related disease in compound heterozygotes is rare. Furthermore,
p.C282Y/p.H63D compound heterozygote hemochromatosis patients
with clinical disease expression frequently have additional risk factors
for iron overload or liver disease.112–115 In conclusion, although
p.C282Y/p.H63D compound heterozygosity is a risk factor for slightly
higher serum iron parameters and mildly increased hepatic iron
stores,112,116–118 this genotype is considered insufﬁcient to cause
hemochromatosis. Likewise, homozygosity for p.H63D is also rarely
associated with hemochromatosis and also not considered to be a
disease-associated genotype.119 This is the reason why genotyping for
p.H63D is not reimbursed in France.
Role, efﬁcacy and efﬁciency of cascade screening
The responses obtained in the survey to the question ‘to whom do you
recommend predictive or carrier testing?’ disclosed a strong divergence
in reported practices. To address this question, a systematic literature
search was performed. Search terms were phrased as PICO where (P)
was deﬁned as patients with HFE-hemochromatosis; interventions (I)
were screening by diagnostic test, measurement of serum iron
parameters (TS, ferritin and/or testing for p.C282Y (p.H63D) variants
in the HFE-gene; compared (C) with no screening; and the expected
outcome (O) was cost, versus prevention of iron overload and
prevention of symptoms. All systematic reviews or meta-analyses,
comparative designs (cohort studies, case–control studies and cross-
sectional studies) and observational studies were eligible for inclusion.
A total of 180 publications were identiﬁed, of which only 14 were
scored as being relevant to answer the research question.
Cascade or family screening in HH can be deﬁned as a genotypic
screening strategy that targets relatives of previously identiﬁed
p.C282Y homozygotes. It is offered to individuals with an increased
risk, usually with some knowledge about the disease, and is aimed to
detect covert homozygotes. In general, it can be considered as less
efﬁcacious (proportion of covert homozygotes detected) but more
efﬁcient (proportion of covert homozygotes detected in relation to the
screening effort) than population screening, and requires the avail-
ability of an index case.121
Data from controlled and uncontrolled family studies demonstrate
that the majority of p.C282Y homozygotes detected by screening of
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ﬁrst-degree relatives of homozygous patients have elevated ‘iron
parameters’ more commonly in men than in women.33,122–127 Data
from uncontrolled family studies indicate that ‘morbidity’ in p.C282Y
homozygous family members of HH patients is considerable, with up
to 42% of them having ﬁbrosis or cirrhosis.33,127,128 This is conﬁrmed
by some, but not all, controlled studies that found an elevated risk of
diseases (particularly rheumatic disorders) in family members of
patients with HH.122,129,130
Data are not consistent on whether iron parameters of relatives of
clinically detected p.C282Y homozygotes differ from relatives of
p.C282Y homozygotes detected by genotyping,124,126 whereas disease
penetrance in p.C282Y homozygotes identiﬁed through family screen-
ing was not found to differ from those identiﬁed by population
screening in both studies on this subject.123,124 Finally, we retrieved
two studies showing that mortality of parents, siblings and children of
p.C282Y homozygotes identiﬁed by clinical presentation or other
means is not higher than that in the general population.122,131
From a study of 291 children of p.C282Y homozygotes, Adams132
recommended that the most cost-effective strategy is to screen spouses
to avoid unnecessary investigation of offspring of probands. In another
(hypothetical) cohort of siblings and children of an affected proband,
and assuming that 80% of HH subjects accumulate iron (of whom
50% develop tissue damage), El-Serag32 compared the cost beneﬁt
analysis of no screening against four screening strategies that
incorporate HFE testing or serum iron indices. They conclude that
in family screening, it is more cost-effective: (i) to screen the spouse
before children when testing two or more children, (ii) to screen the
spouse when children are below the age of consent and (iii) to use
HFE testing instead of serum iron indices. However, it should be
noted that the conclusions of this study strongly depend, among other
factors, on the model assumptions for the prevalence of p.C282Y
carriers in the population, the risk for p.C282Y homozygotes to
develop iron overload and complications and the setting (country).
The prevalence of p.C282Y homozygosity among siblings (~25%),
offspring (~5%) and parents (~5%) of p.C282Y homozygous
probands is increased in comparison with the general Caucasian
population (~0.5%). If we estimate the average risk of the develop-
ment of severe morbidity (eg, liver cirrhosis) for a p.C282Y
homozygote as being 4% (5.6% in males and 1.9% in females),123
the morbidity risk for siblings and offspring of a p.C282Y homozygous
proband can be calculated as 1.0% and 0.2%, respectively. This implies
that 100 siblings, 500 children and 500 parents, respectively, need to be
screened to detect 1 case of cirrhosis. These numbers for family
screening for HH are more favorable than numbers needed to detect a
case in current population screening programs for breast, colon and
cervical cancer, that is 1 in~ 1500–2000.133–135
Finally, we retrieved a study showing that greater awareness of HH
and its potential consequences among probands and family members
are important motivators for them to undergo screening for the
disorder.136
In aggregate, there is sufﬁcient evidence (i) to support screening for
the p.C282Y variant in HFE in ﬁrst-degree family members (siblings,
children and parents) of clinically detected p.C282Y homozygotes or
p.C282Y homozygotes detected otherwise, and (ii) to consider screen-
ing spouses when testing two or more children.
Follow-up of unaffected p.C282Y homozygotes or compound
heterozygotes
It is recognized that early treatment to normalize iron stores increases
the likelihood that the potential serious complications of the disease
are effectively prevented, morbidity and mortality are reduced, and
quality of life is increased.80,122,124,131,137–139 Moreover, it was recently
shown in a cohort of 1086 p.C282Y homozygous patients treated at
early stages that they have a long-term survival superior to the general
population, with a decreased number of deaths by cardiovascular
disease or extra-hepatic cancer,140 further supporting the beneﬁt of
sustained phlebotomy treatment of iron overload in HH. The question
remains, however, as to whether preventive treatment should or not be
recommended to all unaffected but genetically conﬁrmed individuals
because there is no evidence that all of these subjects will necessarily
develop iron overload-related morbidity. To address this question, a
systematic literature search was performed as described above. Search
terms were phrased as PICO where patients (P) were deﬁned as
clinically or biochemically unaffected p.C282Y homozygotes or
p.C282Y/p.H63D compound heterozygotes; interventions (I) were
the follow up of iron indices (TS, SF) and phlebotomy treatment in
comparison (C) with no intervention, and the expected outcome (O)
was the evolution of iron indices and/or development of clinical
symptoms. All systematic reviews or meta-analyses and comparative
designs (cohort studies, case–control studies and cross-sectional
studies) were eligible for inclusion. Case studies and case series with
fewer than 20 patients were excluded. A total of 244 identiﬁed studies
were ﬁrst evaluated for further retrieval based on the question and a
clear deﬁnition of the target population, focusing on population-based
studies of unaffected subjects. The main reasons for exclusion were:
(i) inappropriateness for the question, that is, associations of HFE
genotypes as risk factors for other disease endpoints, studies in
children, prevalence of HFE variants in other clinical settings or in
case-ﬁnding studies and studies of genetic modiﬁers or (iii) possible
bias or indirectness (populations highly selected for geographical
region, blood donors or primary care-based). Of 27 papers kept for
full revision, 10 reported screening studies in the normal
population80,88,103,141–146 and have been already included in previous
reviews or meta-analyses addressing the penetrance of HFE
genotypes.28,34,118,147–149 Four studies reported screening studies in
elderly populations, all conﬁrming the detection of previously
undiagnosed p.C282Y homozygotes with biochemical evidence of iron
overload but no signiﬁcant morbidity.150–153 Finally, and for the
purpose of the speciﬁc outcome of this element (ie, the natural history
of untreated HFE-related hemochromatosis), we selected only studies
with long-term follow-up of untreated subjects. Only six studies
fulﬁlled this criterion: one retrospective154 and two prospective123,155
HH cohort studies of untreated cases; and two prospective population-
based cohort studies; one in Denmark110 and one in Australia
(results published in Gurrin et al111,156 and Allen et al157). The
Copenhagen City Heart Study110 genotyped 9174 individuals and
identiﬁed 23 p.C282Y homozygotes who had been followed for
25 years, none of them having developed clinically overt hemochro-
matosis. The authors conclude that p.C282Y homozygotes identiﬁed
during population screening, and not because of clinically overt HH,
at most need to be screened for manifestations of hemochromatosis
every 10–20 years. The HealthIron study in Australia is a subsample of
the Melbourne Collaborative Cohort Study-MCCS which enrolled
41 514 subjects aged 40–69 years from 1990 to 1994 with
a comprehensive active follow-up from 2003 to 2007 (12 years
follow-up). The results were described in three independent papers.
In 2008, Gurrin and co-workers156 analyzed 86 untreated p.C282Y
homozygotes and predicted the probability of SF and TS at follow-up
exceeding the clinical thresholds from baseline under a multivariate
normal model. They concluded that the probability of a baseline SF of
300–1000 ng/ml to progress to values higher than 1000 ng/ml is
13–35% in males and 16–22% in females. The probability of a normal
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baseline to progress for SF41000 ng/ml if untreated is less than 15%.
Finally, they concluded that the majority of p.C282Y homozygotes
who are likely to develop a SF higher than 1000 ng/ml will have done
so by the age of 55 years. The same authors also analyzed the evolution
of iron indices in 180 compound heterozygotes for p.C282Y and
p.H63D identiﬁed in the HealthIron study.111 They concluded that in
these, the mean iron indices did not change during middle age in
males but SF increases in females. Although maintaining elevated iron
indices during middle age, documented iron overload-related disease
in compound heterozygotes is rare. Finally, in 2010, Allen and
co-workers157 analyzed the evolution of 102 untreated p.C282Y
homozygotes and no evidence was found that those with SF
concentrations below 1000 ng/ml at either baseline or 12 years later
were at increased risk of HH-associated signs and symptoms. These
results raise the question as to whether p.C282Y homozygotes with
SF concentrations o1000 ng/ml should be managed aggressively or
simply monitored to prevent SF rising over the critical threshold.
Ideally, a randomized controlled trial of phlebotomy versus a ‘watchful
waiting’ approach should be performed, but the time required to
produce deﬁnitive results may be prohibitively long.
In conclusion, there is enough evidence to support the notion that
iron indices may progress in some p.C282Y homozygotes or p.C282Y/
p.H63D heterozygotes, supporting the recommendation for a
biochemical follow-up. There is no evidence, however, to support a
speciﬁc follow-up time or schedule. There is insufﬁcient evidence to
recommend phlebotomy treatment in unaffected (ie, without evidence
of hemochromatosis) homozygotes or p.C282Y/p.H63D compound
heterozygotes, but there is still a need for high-quality observational
data on the treatment of HH.
The best practice meeting
In order to develop the initial guidelines draft into a consensus
document, a workshop in the format of an EMQN Best Practice
Meeting (BPM) was held in Porto, Portugal on 14 and 15 May 2014.
The BPM was advertised using the same procedure as for the survey
(see above) and this draft document, together with the topics for
discussion, were made available before the BPM to the respondents
who agreed to participate. The list of meeting attendees and respective
afﬁliations is given in Supplementary Table 1.
As a result of the meeting, an agreed set of best practice guidelines
was updated for genetic diagnostic and predictive testing for HFE-
related HH and for reporting the results of such testing. In addition,
some basic guidelines were also developed for testing and reporting the
rarer forms of non-HFE-related HH. Resulting recommendations are
based on available published evidence scored according to the GRADE
system for quality and strength of evidence. If the quality of evidence
was low or very low, the proposed recommendations resulted from the
experts’ collective decision, this information being provided in the
document. A ﬁnal version of the consensus document (corrections
and amendments performed according to the results of the BPM) was
reviewed by the drafting team, circulated among the BPM participants
for revision and further amendments and was ﬁnally approved by the
EMQN board.
The BPM provided the opportunity not only to discuss the
controversial topics previously reviewed through the systematic
literature search and its implications for future research (described
above), but also to discuss some other relevant topics described here.
Questions regarding nomenclature and case deﬁnition
It became apparent during the BPM that questions regarding the
nomenclature and case deﬁnition of HH are among the major causes
of confusion when dealing with the interpretation of test results and
reporting practices. Some participants pointed to the fact that, in face
of the increasing awareness and knowledge of the pathogenesis of iron
overload disorders, some concepts relating to HH deﬁnition should be
revised.
The term Hemochromatosis was ﬁrst coined by von
Recklinghausen158 in 1889 following the description of its iron-
related pathology. The clinical characteristics of the disease were later
described by John Sheldon159 in 1934 after a systematic review of
autopsy cases, and the autosomal recessive mode of transmission was
demonstrated by Simon and co-workers160 in 1977 following the
discovery of its association to HLA. Since that time, a typical
phenotypic characterization of patients was necessary to deﬁne HH,
including the demonstration of severe liver iron overload. The
selection of HH patients based on a strict phenotypic case deﬁnition
was fundamental to permit the positional cloning of the HH-
associated gene. After the discovery in 1996 of the genetic defect in
HFE, which explained over 80% of previously phenotypically
characterized cases,48 a genetic deﬁnition of HH became available,
and a pre-symptomatic diagnosis in subjects with less severe forms of
iron overload became feasible. These advances, however, also brought
some confusion among clinicians about what constitutes the case
deﬁnition of HH.27 Although a purely genetic deﬁnition cannot be
accepted, owing to the low penetrance and variable clinical expression
of p.C282Y homozygosity in HFE, a purely phenotypic case deﬁnition
is also not acceptable because it will necessarily combine many
different types of iron overload (genetic and acquired) defeating the
original purpose of having a case deﬁnition, that is, to characterize the
natural history, disease prognosis and, most importantly, to guide its
treatment and/or prevention.27 For the purpose of nomenclature
harmonization, we refer in this document to HFE-related HH
according to the case deﬁnition agreed on the 2010 EASL Clinical
Practice Guidelines for HFE Hemochromatosis, that is, as the
occurrence of increased body iron stores associated with homozygosity
for the p.C282Y HFE variant, with or without clinical symptoms.28
The other rare forms of HH are here classiﬁed as non-HFE-related
HH in harmonization with the classiﬁcation agreed in the AASLD
Practice Guideline of 2011.4 They can be generally deﬁned as increased
body iron stores not associated with homozygosity for the p.C282Y HFE
variant but attributed to pathogenic variants in other iron-related genes,
namely hemojuvelin (HJV), hepcidin (HAMP) and transferrin
receptor 2 (TFR2). For all of these genes, the pathogenesis of HH
involves inadequate or ineffective production or hepcidin-mediated
downregulation of ferroportin with consequent increase in iron
absorption and iron export from macrophages. In the case of
ferroportin variants, when they are associated with an excessive
ferroportin-mediated iron export (gain-of-function variants, or type
B), they cause a phenotype similar to the one observed in the classical
HFE-related HH with elevated TS, hyperferritinemia and iron
overload mostly affecting hepatocytes, but with normal or elevated
(rather than low) hepcidin levels.25 In this case, ferroportin disease is
included in the differential diagnosis of non-HFE-related hemochro-
matosis. In the case of the most common loss-of-function ferroportin
variants (type A), the interaction between hepcidin and ferroportin is
altered affecting iron export from cells with consequent accumulation
in Kupffer cells and other macrophages, and is expressed by
hyperferritinemia with high/normal or low TS.161 Although originally
described as autosomal dominant hemochromatosis162 and referred to
in the OMIM database as type 4 hemochromatosis, strictly speaking, it
does not ﬁt into the classical deﬁnition of HH which implies an
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inappropriately high absorption of iron by the gastrointestinal mucosa
with consequent increased iron storage.
Controversy remains regarding the deﬁnition of HH associated with
HFE variants other than p.C282Y, and no established consensus has
been published before. The most frequently found HFE variant in all
populations is p.H63D, and this was originally described by Feder and
co-workers48 as a common variant associated with iron overload in
patients who were p.C282Y heterozygotes. It should be noted that the
two variants are always inherited in trans (on separate alleles) because
they arose as independent founder alleles. After this original report, it
was common practice to classify individuals with the p.C282Y and
p.H63D variants inherited in compound heterozygosity as an HH-
associated genotype. This practice, however, was later challenged by
the growing evidence that p.C282Y/p.H63D compound heterozygous
subjects have a distinct iron overload phenotype (mild to moderate)
normally associated with the presence of other comorbidity factors,
namely alcohol abuse or dysmetabolic iron overload syndrome.28,111
Therefore, notwithstanding a role of p.H63D as a susceptibility factor
for increased iron overload,118,147,163 for practical clinical purposes,
p.C282Y/p.H63D compound heterozygotes and p.H63D homozygotes
are not classiﬁed as HFE-associated HH (following the most recent
EASL guidelines), and it is recommended that in patients with these
genotypes and iron overload, other genetic or environmental risk
factors should be examined.28 Another variant, p.S65C, reported as a
normal variant in the European population,164 has also been described
as a susceptibility allele in patients with iron overload, particularly in
association with heavy alcohol consumption,146,165 but no evidence
has ever been provided to support a causative role in HH. Therefore,
neither testing nor reporting the presence of p.S65C is recommended
in the diagnosis of HFE-related HH. Some very rare HFE variants or
deletions associated with disruption of the HFE protein function have
been described in compound heterozygosity with p.C282Y in severe
cases of HH.12 Although such patients can be classiﬁed as HFE-related
HH, because of their rarity and necessary speciﬁc molecular workup
for diagnosis, we suggest distinguishing these hemochromatosis
variants from classical HFE-associated HH and including them in
the classiﬁcation of Rare Hereditary Hemochromatosis. Finally, it
should be noted that in many clinical reports and disease databases,
different nomenclatures have been used to classify HH and this fact
may lead to confusion among clinicians and laboratory geneticists.
A summary of the nomenclature used in this document, the disease
names, synonyms, symbols, databases reference numbers (ORPHA-
NET and OMIM (the Online Mendelian Inheritance of Man
database)), the respective genes/loci and cytogenetic positions, as well
as their major pathological and clinical deﬁning characteristics, is given
in Table 1.
The value of recognized Expert Centers
The French Reference Centre for Rare Iron Overload Diseases of
Genetic Origin was created in 2007, as part of the ﬁrst French National
Plan for Rare Diseases (which started in 2005). Located at the
University Hospital Pontchaillou in Rennes, and beneﬁting from a
speciﬁc budget, it works in close collaboration with nine centers of
competence spread across the country. The goal of this network of
expertise is to contribute to the equity of medical care and research
activities within the broad spectrum of rare diseases. The speciﬁc
diseases involved correspond essentially to non HFE-related genetic
iron overload diseases (type 2, 3 or 4 hemochromatosis), and to some
other entities such as hereditary aceruloplasminemia and atransferri-
nemia. It also includes exceptional forms of HFE-related hemochro-
matosis involving rare variants. From the diagnostic viewpoint, the
reference center analyzes all referred cases of unexplained iron excess
using a multidisciplinary approach, in order to select those who
warrant targeted genetic exploration. The center leads in proposing
diagnostic and therapeutic recommendations to be disseminated to the
medical community. With regard to basic and clinical research, the
center proposes and coordinates various themes covering epidemio-
logical, diagnostic and therapeutic aspects, in association with the
recognized centers of competence. One of the hot topics today,
considering increasingly efﬁcient techniques in the ﬁeld of molecular
genetics, is to develop functional tests to aid in the prediction of
deleterious effects associated with previously unclassiﬁed variants.
A major aim is the integration, as soon as possible, of the reference
center within a European network for rational sharing of diagnostic
tools, homogenization of diagnostic and therapeutic practices, and
coordination of research actions. There remains a great disparity in
Europe regarding the policy on rare diseases, from countries that have
recently decided to develop a plan/strategy to those whose national
plans and strategies are fully implemented. However, many European
medical, scientiﬁc and patient organizations are actively engaged in
this cause, which gives conﬁdence in future improvement of the
management of rare diseases, including those related to genetic iron
overload.
The future of NGS in clinical practice
Historically, genetic testing for HH has developed from detection of
the common HFE variants through to conventional DNA sequencing
of the HFE gene, and/or other genes implicated in rarer hereditary
iron overload disorders. With the advent of NGS, it is now possible to
investigate, on a research basis, the genetics of rare or complex
disorders, based on whole-exome or -genome analyses. The technol-
ogy for sequencing multiple genes simultaneously is developing
rapidly, with no ﬁrm consensus on approaches to diagnostic testing.
However, guidance on consensus standards for identifying and
reporting variants identiﬁed using NGS approaches has been
produced.166 In a diagnostic context, NGS based on targeted gene
analysis is being introduced, including panels linked to disorders of
iron metabolism. For routine type 1 HH analysis the current
approach, based on recognized phenotypic parameters to identify
index cases that have a phenotype meriting p.C282Y genotyping prior
to relevant predictive or diagnostic testing in appropriate family
members, is likely to remain in place for the foreseeable future.
Where NGS gene panel analysis will increasingly have a role is in those
rare cases where there is documented evidence of iron overload and
initial screening approaches do not detect recognized variants or
variants associated with the phenotype. This will apply not only to type
1 HH but also to the other forms discussed in this document. In such
circumstances, iron metabolism gene panels can be applied to facilitate
detection of rare variants, ultimately contributing to our under-
standing of these disorders. For this strategy to be successful, such
investigations will be best performed by referral to a small number of
specialist centers in order to ensure both a cost-effective approach and
the availability of the necessary expertise in the interpretation of results
obtained, particularly when interpreting the likely signiﬁcance of any
unclassiﬁed variants detected.
A ﬁnal remark: the patients’ expectations and the role of General
Practitioners in the management of HH
In the frame of the present guidelines, a survey was also conducted by
the European Federation of Associations of Patients with Hemochro-
matosis (EFAPH) on the perceptions of patients about genetic
information namely on the sources used or trusted. The results of
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the survey provided, for the ﬁrst time, a basis for recommendations
intended to improve communication between patients and health-care
providers regarding genetic information and suggests that more efforts
should be put in awareness, motivation and education among General
Practitioners regarding HH management.167
THE GUIDELINES—EVIDENCE-BASED RECOMMENDATIONS
These guidelines offer an overview of the recommended basis for
genetic testing referral where there is a suspicion of type 1 HH or rare
forms of HFE-related and non-HFE-related HH, along with predictive
testing of adult ﬁrst-degree relatives of subjects conﬁrmed to have HH
by molecular analysis. They illustrate the minimum expected inter-
pretation standards for these disorders where the correlation between
the clinical phenotype and genotype must be considered prior to
referral for investigation and reporting.
Methods and testing strategies
A variety of methods for HFE genotyping are in use by laboratories
participating in the EMQN EQA scheme for HFE HH. The most
common testing strategies in use detect the p.C282Y (c.845G4A) and
p.H63D (c.187C4G) variants and are based on PCR/restriction
enzyme digestion or various allele-speciﬁc ampliﬁcation strategies.
The vast majority of HFE-related hemochromatosis is associated
with homozygosity for p.C282Y. p.C282Y/p.H63D compound
heterozygosity may be a risk factor predisposing to mild or
moderate forms of iron overload when in association with
comorbidity factors, for example, alcohol or metabolic
syndrome.3,111 The association of homozygosity for p.H63D with
iron overload is debated and requires further clinical research, but
it is now recommended that other risk factors or other genetic
causes should be sought and investigated in patients with this
genotype and demonstrated iron overload.3 Testing for these two
HFE variants can be performed either sequentially or simulta-
neously. Sequential testing, starting with p.C282Y, will avoid
detection of p.H63D homozygotes, and this has been considered
by most experts as an advantage. However, this reﬂex testing
approach increases the turn-around time and overall cost. A
simultaneous testing strategy should be weighed against the
possibility of creating anxiety or unnecessary investigation. The
laboratory should take these factors into account when deciding to
use this strategy. In any case, when a method detects both variants
concurrently, which is generally the case, there is an obligation to
report the complete result.
There is no supporting evidence for a role of the p.S65C variant
(c.193A4T) in clinically manifest HH (p.S65C is a normal variant in
the general European population).146,164,168 Therefore, testing for the
p.S65C variant is not recommended for diagnostic purposes; if
detected as an incidental ﬁnding, it should not be reported to avoid
possible over-interpretation of its signiﬁcance.
Guidelines from the European Society of Human Genetics and the
American College of Medical Genetics recommend not testing minors
for carrier status for late-onset disorders. When requested by parents
in this situation, local and international practice and regulations
should be followed/recommended by the health careers.
Quality assurance framework
The EMQN external quality assessment (EQA) scheme for HFE
continues to detect both genotyping errors and variable quality of
interpretive comments. This indicates the continued importance of
quality assurance and improvement. It is recommended that testing
laboratories are accredited to international standards (ISO 15189 or
equivalent).169,170 The techniques used should be validated in-house
with appropriate sample types and numbers. If CE-marked IVD kits
are used, in-house veriﬁcation should be performed. Laboratories
reporting HFE testing results should participate annually in EQA. EQA
provides a long-term, retrospective assessment of laboratory perfor-
mance, allowing laboratories to demonstrate consensus with their
peers and providing information on inter-method comparability.
Unless dictated by legislation, the choice of EQA provider lies with
the laboratory, but the use of an EQA programme that assesses
reporting as well as genotyping and that is accredited to ISO 17043 is
recommended, wherever possible.
Recommendations for HFE testing strategies:
 Laboratories providing testing for HFE-associated HH should test
for p.C282Y (1A).
 According to local practice, p.H63D can be a considered an optional
complementary test that can be offered sequentially or simulta-
neously to p.C282Y testing (2C).
 Testing for p.S65C should not be offered; if detected as an incidental
ﬁnding, it should not be reported (1B).
 It is recommended that testing laboratories are accredited according
to international standards (ISO 15189 or equivalent).
 It is recommended that genetic testing for suspected rare forms of
hemochromatosis should be performed by specialist centers.
Criteria for diagnostic and predictive testing
These have been extensively covered in published clinical guidelines
and reports (summarized in 'Results of the survey on current practices
of genetic diagnosis of HH', see Swinkels et al9 and Berwouts et al170).
In current clinical practice, patients are often referred for HH genetic
testing based on a diverse range of indicators. These include isolated
raised SF (hyperferritinemia), raised transaminases, type 2 diabetes
and arthralgia. This situation has arisen owing to overestimations of
the penetrance and clinical impact of p.C282Y homozygosity and these
patient groups are no longer considered to be appropriate for HFE-
HH genetic testing. In the absence of raised TS, there is no evidence to
support genetic testing for the p.C282Y variant in an index case solely
for clinical reasons.
Given the importance of the TS result, it should be noted that the
concept of ‘elevated transferrin saturation’ varies, ranging from levels
of 45 to 60%. A higher cutoff value is expected to have a superior
positive predictive value and is useful in populations where reference
values are higher, usually associated with lifestyle habits including
regular daily alcohol consumption.29 Lower cutoff values are more
sensitive (with a higher negative predictive value), but less speciﬁc.
They may facilitate earlier detection of iron overload but will increase
false-positive detection rates.171 Elevated SF (ie, exceeding the local
upper limit of the reference range) is a potential biochemical marker
of iron overload but is not speciﬁc for HH. Therefore, conﬁrmed
hyperferritinemia should prompt testing for TS before genetic testing.
If TS is normal, alternative causes of hyperferritinemia should be
sought, such as indicators of inﬂammation and liver disease, most
commonly observed in the presence of metabolic syndrome or fatty
liver disease.31 Conversely, in the presence of high TS with normal SF
values, a genetic test should be considered. Testing for rare variants in
HFE, or other genes associated with non-HFE-related HH, should be
reserved for highly selected cases with documented, unexplained iron
overload (increased body iron stores) that test negative for p.C282Y
homozygosity. These rare cases should be referred to specialist centers
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offering appropriate molecular diagnosis and expert advice on iron
overload disorders.
Predictive testing of ﬁrst-degree relatives of subjects conﬁrmed to
have HH by molecular analysis
Because the prevalence of individuals at risk to develop morbidity is
increased among ﬁrst-degree relatives of index cases, their identiﬁca-
tion through predictive testing is appropriate. Genetic testing of adult
asymptomatic individuals should be undertaken only after appropriate
counselling addressing the pros and cons of testing as well as the
possible clinical consequences relating to the test result.
p.C282Y homozygotes. Genetic testing of adult ﬁrst-degree relatives of
p.C282Y homozygous cases aims to identify covert homozygotes in the
family so that appropriate management can then be instigated. The
low penetrance of p.C282Y homozygosity should be clearly explained
before testing. When a p.C282Y heterozygote is identiﬁed by this
process, further cascade testing of his ﬁrst-degree relatives is not
recommended. This rationale is based on low morbidity when the
further reduced risk for inheritance of p.C282Y homozygosity in these
individuals is combined with the low penetrance of the clinical
phenotype of HH in homozygotes.
p.C282Y/p.H63D compound heterozygotes. Owing to the relatively low
risk of morbidity and the consequently low clinical efﬁciency of
screening, consensus was not reached in order to recommend genetic
testing of clinically asymptomatic adult ﬁrst-degree relatives of
p.C282Y/p.H63D compound heterozygotes.
Other HFE genotypes. Owing to the relatively low risk of morbidity
and the low penetrance, genetic testing of clinically asymptomatic
adult ﬁrst-degree relatives of p.C282Y heterozygotes or p.H63D
homozygotes is not recommended.
Rare forms of HFE- or non-HF- related HH
Genetic testing of clinically asymptomatic adult ﬁrst-degree relatives of
individuals with these rare conditions aims to identify additional
individuals at risk of these rare forms of HH and it is therefore
recommended.
Recommendations for diagnostic and predictive testing:
 Population screening for the p.C282Y variant is not currently
recommended (1B).
 It is considered to be good practice to conﬁrm elevated TS before
HFE genetic diagnosis testing (1B).
 Testing adult siblings (brothers and sisters) of p.C282Y homo-
zygotes is recommended owing to the increased risk of p.C282Y
homozygosity and related increased morbidity (1B).
 Testing adult offspring of p.C282Y homozygotes is recommended
owing to increased risk of p.C282Y homozygosity and related
increased morbidity (1C).
 Testing asymptomatic parents of p.C282Y homozygotes is not
recommended systematically but rather as a clinical decision
depending on their age, sex and ferritin, all three inﬂuencing the
probability to develop severe iron overload (1C).
 Systematic testing of adult ﬁrst-degree relatives of p.C282Y hetero-
zygotes is not currently recommended, in the absence of evidence of
beneﬁt (2C).
 HFE testing of minors is not recommended (1B).
 Prenatal diagnosis is not appropriate in HFE-related HH because it
is a treatable, adult onset condition (1C).
 Genetic testing of ﬁrst-degree relatives of rare HFE-related and non-
HFE related HH should be performed by specialist/reference
centers/laboratories (2C).
Reporting of HFE genotyping results
The primary role for HFE genetic testing is to conﬁrm or exclude a
diagnosis of HFE-related HH, or to predict the risk for this condition.
No solid evidence has been provided to support the clinical utility of
HFE genotyping as a susceptibility test for iron overload in general.
Analysis of current practice in HFE molecular testing reveals that a
growing number of clinicians routinely request this genetic test but
that it conﬁrms a diagnosis of HFE-related HH in only a small
proportion of cases.1 If not properly informed as to the relative
signiﬁcance of each genotype combination, it is possible that some
clinicians may incorrectly assume a diagnosis of HH for genotypes
other than p.C282Y homozygosity, with undesirable consequences
relating to both patient management and counselling information
provided to relevant family members. It is therefore recommended
that when reporting HFE genotyping results, a clear statement be given
regarding the requested reason for testing, and that interpretative
comments are given in a case-speciﬁc context. This implies, of course,
that a clear indication of the reason for testing is provided by the
requesting clinician.
Additional interpretative comments on reports may refer to: the
implications of the test result for other family members, the need to
establish differential diagnosis with other forms of iron overload and
suggested follow-up strategies in the case of predictive detection. For
example, the identiﬁcation of an asymptomatic or previously
undetected p.C282Y homozygous family member should prompt
evaluation of their iron indices and establishment of an appropriate
follow-up program. If asymptomatic p.C282Y/p.H63D compound
heterozygotes are detected, recommendations regarding monitoring
of iron indices are more controversial and a consensus was not
reached yet. The fact that individuals with this genotype may go on to
exhibit a mild-to-moderate iron overload phenotype, normally
associated with other comorbidity factors such as alcohol abuse or
metabolic syndrome,3,111 may constitute an argument to recommend
referral to a specialist for monitoring of iron indices and lifestyle habits.
Nevertheless, care should be taken not to create unnecessary anxiety in
apparently healthy subjects with a compound heterozygous genotype.
Although they might have elevated iron indices, documented iron
overload-related disease in subjects with this genotype is rare.111
Reporting scenarios
The following provides basic guidelines for reporting HFE test results
based on reasons for referral and resulting genotypes. Points regarded
as essential are highlighted in italics. It should be stressed that these
guidelines are presented under the assumption that HFE genotyping is
performed to conﬁrm, exclude or predict the most common HFE-
related forms of HH and they do not cover rare or population-speciﬁc
alternative variants in HFE. Other forms of iron overload and other
types of HH exist and further investigation may be suggested where
relevant clinical and biochemical features indicate. In those rare cases
with a strongly suggestive phenotype that are not conﬁrmed to be p.
C282Y homozygous, investigation for other genetic forms of HH or
referral to a specialist unit may be suggested. However, it must be
stressed that these are rare and should only be considered in cases
where there is a documented severe iron overload that remains
unexplained after exclusion of other causes. Reference to the implica-
tions of the HFE test result for other adult family members and
recommendations for genetic counselling should be reserved only for
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individuals carrying the p.C282Y variant; otherwise it may create
unnecessary anxiety. In cases where screening is performed with
additional genetic and/or phenotypic data, reporting recommenda-
tions may be adapted to reﬂect individual case scenarios more closely.
A summary of basic interpretive comments relating to HFE-related
HH is given in Table 2.
Diagnostic reporting scenarios
Diagnostic referral (ie, affected individual); homozygous p.C282Y.
The individual is homozygous for the p.Cys282Tyr variant in the
HFE gene.
Reports should state that, in the presence of a suggestive phenotype, this
genotype supports the diagnosis of HFE-related HH. Formal diagnosis
requires demonstration of increased hepatic iron stores.
Additional comments may refer to implications of the result for
other adult ﬁrst-degree family members and recommend genetic
counselling for predictive/carrier testing. It is not appropriate to
simply state that all relatives must/should be tested. Genetic testing
for p.C282Y and biochemical testing for iron overload is recom-
mended in ﬁrst-degree adult family members.
Diagnostic referral (ie, affected individual); compound heterozygous
p.C282Y/p.H63D C282Y. Patients with this genotype may have iron
overload but to a much lesser degree than p.C282Y homozygous HH
patients, and usually in association with other risk factors.111 Although
compound heterozygotes might maintain elevated iron indices during
middle age, documented iron overload-related disease is rare and this
genotype should therefore have a different interpretation than for a
p.C282Y homozygote referred on the same basis. The genotype is
common among the general European population and a reference to
the local estimated frequency may be given.
The individual is a carrier of both the p.Cys282Tyr and the
p.His63Asp variants in the HFE gene.
Reports should state that the diagnosis of the most common
HFE-related HH is excluded. This genotype may predispose to
mild / moderate iron overload. In patients with iron overload, other
contributing factors should be considered (most commonly, alcohol
consumption, fatty liver disease, and/or metabolic syndrome).
In patients with a severe iron overload phenotype, other rare forms of
HH cannot be excluded.
Additional comments may refer to implications of the result for other
adult ﬁrst-degree family members, and genetic counselling may be
considered. It is not considered appropriate to recommend predictive/
carrier testing to all relatives (cascade family screening). Biochemical
testing of ﬁrst-degree adult family members should be considered.
Diagnostic referral (ie, affected individual); heterozygous p.C282Y. It
has been documented that some p.C282Y heterozygotes may exhibit
mild to moderately raised indices of iron overload,106 although
complications due to iron overload are very rare and may be
inﬂuenced by additional factors, both genetic and environmental.
The individual is a carrier of the p.Cys282Tyr variant in the HFE gene.
Reports should state that the diagnosis of the most common HFE-
related HH is excluded.
In patients with a severe iron overload phenotype, other rare forms of
HH cannot be excluded.
Additional comments may refer to implications of the result for other
adult ﬁrst-degree family members, and genetic counselling may be
considered. It is not considered appropriate to recommend predictive/
carrier testing to all relatives (cascade family screening). Biochemical
testing of ﬁrst-degree adult family members may be considered.
Diagnostic referral (ie, affected individual); homozygous p.H63D. It
has been suggested that p.H63D homozygotes may have a slight risk of
iron overload.118,147,163 Despite some geographical variation118 this
genotype is present in about 3% of the general European population
and its signiﬁcance as a susceptibility factor remains uncertain.
The individual is homozygous for the p.His63Asp variant in the
HFE gene.
Reports should state that the diagnosis of the most common HFE-
related HH is excluded. This genotype may be associated with a slight
increase of ferritin and TS. Other causes of iron overload should be
considered.
In patients with a severe iron overload phenotype, other rare forms of
HH cannot be excluded.
Additional comments may refer to the uncertainty and controversy
regarding the role of p.H63D as a risk factor for mild to moderate iron
overload, in the presence of other causes of iron overload (eg, fatty
liver disease and/or metabolic syndrome). It is not appropriate to refer
to implications of this genotype for other adult family members.
Diagnostic referral (ie, affected individual); heterozygous p.H63D.
The individual is a carrier of the p.His63Asp variant in the HFE gene.
This variant is present at a high frequency in the general population. The
diagnosis of the most common HFE-related HH is excluded and other
causes of iron overload should be considered.
In patients with a severe iron overload phenotype, other rare forms of
HH cannot be excluded.
It is not appropriate to refer to implications of this genotype for
other family members.
Diagnostic referral (ie, affected individual); detection of the p.S65C
variant. Given the absence of any clinical merit, testing for p.S65C is
not recommended. If p.S65C is detected by the analysis method in use,
this variant should not be reported. Therefore, report wording should
treat such diagnostic cases as ‘p.C282Y and p.H63D variants not
detected’ (see below).
Diagnostic referral (ie, affected individual); p.C282Y and p.H63D
variants not detected. Reports should state that the diagnosis of the
most common HFE-related HH is excluded and other causes of iron
overload should be considered.
In patients with a severe iron overload phenotype, other rare forms of
HH cannot be excluded.
Predictive reporting scenarios. The guidance for reporting predictive/
carrier testing results are written under the assumption that the iron
status of the individual is not known and that appropriate genetic
counselling has been performed prior to testing.
In cases where screening is performed with additional genetic
and/or phenotypic data, reporting recommendations may be adapted
to reﬂect individual case scenarios more closely.
Predictive referral (ie, individual currently unaffected); homozygous
p.C282Y. The individual is homozygous for the p.Cys282Tyr variant in
the HFE gene. He is at an increased risk of developing HFE-related HH,
and it is recommended that serum iron parameters (TS and ferritin) be
monitored.
The report may refer to implications of the result for other adult
family members and suggest that genetic counselling be considered if
not previously performed. Given the variable penetrance of p.C282Y
homozygosity, it is not considered appropriate to state that the
individual has, or will go on to develop, HH if no evidence of
phenotypic expression is given.
Hereditary hemochromatosis guidelines
G Porto et al
490
European Journal of Human Genetics
Predictive referral (ie, individual currently unaffected); compound
heterozygous p.C282Y/p.H63D. The individual is a carrier of both the
p.Cys282Tyr and p.His63Asp variants in the HFE gene and is at low risk
of developing signiﬁcant iron overload. He may be at risk of developing
mild-to-moderate iron overload if there is an association with other
comorbidity factors (eg, alcohol abuse, fatty liver disease and/or metabolic
syndrome).
Additional comments may suggest monitoring of iron indices.
It is not considered appropriate to recommend predictive/carrier
testing to relatives.
Predictive referral (ie, individual currently unaffected); all other non-p.
C282Y-carrying genotypes. The individual is not a carrier of the
p.Cys282Tyr variant in the HFE gene and he is at no increased risk of
developing HFE-related HH.
Predictive referral (ie, individual currently unaffected); heterozygous p.
C282Y. The individual is a carrier of the p.Cys282Tyr variant in the
HFE gene and he is at no increased risk of developing HFE-related HH.
It is not considered appropriate to recommend predictive/carrier
testing to relatives.
Reporting results for rare forms of HFE- or non-HFE-related HH
General information on requirements for variant reporting can be
found in appropriate nomenclature guidelines. It is recommended that
Human Genome Variation Society (HGVS) convention is followed
when reporting variants and unclassiﬁed variants.172,173 Information
on previously described variants can be found in available
databases,174 however, the creation of locus-speciﬁc databases listing
pathogenic and non-pathogenic variants is encouraged. The following
represents some basic guidelines for reporting test results based on
possible scenarios.
Reporting on a known causative variant in the tested genes (HFE2
(HJV), HAMP, TFR2 or SLC40A1) in an affected index case
The report should state that a causative variant(s) has been detected
and that this conﬁrms the clinical diagnosis.
The report should include a description of the reason why a
particular variant(s) is considered causative, drawing on all relevant
supporting data including the scientiﬁc published data.
Determination of the parental origin of the detected variant(s) is
advised.
Predictive/carrier testing of relatives at risk should be offered after
appropriate genetic counselling.
Ferroportin disease exhibits autosomal dominant inheritance asso-
ciated with, in its usual form (type A), hepatic and splenic iron
overload in the absence of increased TS. In the type B form, its
phenotype mimics that of classical HH. Heterozygous SLC40A1
variants may be sufﬁcient to cause these particular phenotypes and
this should be taken into account when conducting family screening.
Reporting on a novel variant in the tested genes (HFE, HFE2 [HJV],
HAMP, TFR2 or SLC40A1) in an affected index case
If the genetic testing procedure has identiﬁed an unclassiﬁed variant as
the only sequence change, this should be interpreted according to
reporting of unclassiﬁed variants guidelines.173
GENERAL GUIDELINES FOR REPORTING
General information on requirements for variant reporting can be
found in ISO 15189,170 the OECD Guidelines for Quality Assurance in
Molecular Genetic Testing and the Swiss Medical Genetics Society
guidelines for reporting.38,175
General report contents
According to the international standards for accreditation, reports
should be written in a clear, concise, accurate, fully interpretative,
credible and authoritative format. Importantly, they should specify the
scope of the investigation, that is, if testing is for HFE-related HH, or if
the rarer forms are being considered.
Nomenclature
It is considered essential that reports follow HGVS guidelines for
reporting variants.172 Use of HGVS requires coding changes at the
Table 2 Summary of diagnostic and predictive interpretation comments for the HFE gene p.C282Y and p.H63D related genotypesa
Genotype Interpretation (diagnostic test) Interpretation (predictive test)
Homozygous p.C282Y NM_000410.3:c.
[845G4A];[845G4A]
Compatible with the diagnosis of HFE-related HH in the
presence of documented evidence of iron overload.
At risk of developing HFE-related HH. Prompt
assessment of iron parameters indicated.
Compound heterozygous p.C282Y/p.H63D
NM_000410.3:c.[187C4G];[845G4A]
Excludes the diagnosis of the most common form of HFE-related
HH; genotype consistent with mild to moderate iron overload;
Prompt the search for other causes (eg, alcohol consumption,
fatty liver disease and/or metabolic syndrome).
At low risk for development of signiﬁcant iron
overload. May be at-risk of developing mild to moderate
iron overload in association with comorbid factors.
Heterozygous p.C282Y NM_000410.3:c.
[845G4A];[= ]
Excludes the diagnosis of the most common HFE-related HH.
Other causes of iron overload should be considered.
Carrier for HFE-related HH. Is at no increased
risk of developing HFE-related HH.
Homozygous p.H63D NM_000410.3:c.
[187C4G];[187C4G]
Excludes the diagnosis of the most common HFE-related HH.
Other causes of iron overload should be considered.
At no increased risk of developing HFE-related HH.
Heterozygous p.H63D NM_000410.3:c.
[187C4G];[= ]
Excludes the diagnosis of the most common HFE-related HH.
Other causes of iron overload should be considered.
At no increased risk of developing HFE-related HH.
p.S65C detected NM_000410.3:
c.193 A4T
In the absence of supporting evidence for a role in HH, testing
for the p.S65C variant is not recommended for diagnostic purposes.
If detected as an incidental ﬁnding it should not be reported but
treated as ‘no variant detected’.
aThis table summarizes key interpretation points only and should be read in conjunction with the main ‘diagnostic reporting scenarios’ text.
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nucleotide level and citation of the appropriate reference sequence. In
addition, protein-based coding is permissible (three-letter). However,
this should not be at the expense of a clear and succinct description of
the genotype. Where both common and formal names for variants are
used, these should be formatted in such a way as to avoid confusion to
the report recipient.
The correct HGVS coding of the principal genotypes is given in
Table 2. HGVS nomenclature can be checked using the freely-
accessible program Mutalyzer.176
CONCLUSION
An agreed set of best practice guidelines has now been updated for
diagnostic, predictive and carrier testing for HFE-related HH and for
reporting the results of such testing. In addition, some basic guidelines
have been developed for testing and reporting rarer forms of non-HFE-
related HH. Consensus and consultation processes for this document
occurred within the framework of a best practice meeting where,
following prior dissemination of related literature, relevant topics were
discussed by a group of experts. The resulting recommendations are
based on the available published evidence, and the GRADE system for
scoring the quality of evidence and strength of recommendations was
applied.36 This process has been translated into guidance when
reporting variants associated with iron overload disorders.
CONFLICT OF INTEREST
The authors declare no conﬂict of interest.
ACKNOWLEDGEMENTS
We wish to thank Prof. David Barton, Chair of the Management Board of the
European Molecular Quality Network (http://www.emqn.org) for promoting
the revision of the guidelines, for funding and facilitating the BPM and for
funding topublish the manuscript as an open access document. We
acknowledge Jacques Rochette, from the Laboratoire de Génétique, Hôpital Sud
CBH, CHU-AMIENS, responsible for the French Network involved in
molecular diagnosis ofhaemochromatosis, for kindly revising the ﬁrst draft of
this manuscript, Monique Wessels from Knowledge Institute of Medical
Specialists (KiMS) in the Netherlands for her contribution in the literature
search and Emerência Teixeira for her support inthe manuscript editing.
We would also like to acknowledge IBMC, the Institute for Molecular and
Cellular Biology, Porto, Portugal, and its staff who kindly provided the facilities
and means to host there the Best Practice Meeting on the 14–15 May 2014, and
thank all the participants of this meeting which resulted in the ﬁnal drafting of
the guidelines.
AUTHOR CONTRIBUTIONS
GP led the HH guidelines project, coordinated feedback among the drafting
team members, analyzed data and co-organized the Best Practice Meeting
(BPM). GP, PB, DWS and HZ constituted the guidelines drafting team. They
designed and validated the questionnaire on current laboratory practices used
for the online survey. This was organized, analyzed and reported by OK and
GP. The drafting team was responsible for the systematic literature search and/
or leading the BPM discussions on the topics: the clinical value of testing for p.
H63D (HZ); role, efﬁcacy and efﬁciency of cascade screening (DWS); follow-up
of unaffected p.C282Y homozygotes and p.C282Y/p.H63D compound hetero-
zygotes (GP) and the value of expertise centers for HH (PB). SK revised and
approved the ﬁrst draft, led the BPM discussion on the topic of the future of
NGS gene panels and was responsible for drafting the ﬁnal version of the
guidelines. SP organized the BPM. IA analyzed data, revised the manuscript and
participated in the local organization of the BPM. MM actively participated in
the BPM, and, in his capacity as EMQN guideline reviewer, revised and
approved the ﬁnal version of the document.
1 Fleming RE, Ponka P: Iron overload in human disease. N Engl J Med 2012; 366:
348–359.
2 Mayr R, Janecke AR, Schranz M et al: Ferroportin disease: a systematic meta-analysis
of clinical and molecular ﬁndings. J Hepatol 2010; 53: 941–949.
3 European Association For The Study Of The Liver: EASL clinical practice guidelines for
HFE hemochromatosis. J Hepatol 2010; 53: 3–22.
4 Bacon BR, Adams PC, Kowdley KV, Powell LW, Tavill AS: Diagnosis and management
of hemochromatosis: 2011 practice guideline by the American Association for the
Study of Liver Diseases. Hepatology 2011; 54: 328–343.
5 van Bokhoven MA, van Deursen CT, Swinkels DW: Diagnosis and management of
hereditary haemochromatosis. BMJ 2011; 342: c7251.
6 Brissot P: Diagnosis and current treatments for primary iron overload. Am J Hematol
2007; 82: 1140–1141.
7 Adams PC, Barton JC: How I treat hemochromatosis. Blood 2010; 116:
317–325.
8 Zoller H, Cox TM: Hemochromatosis: genetic testing and clinical practice. Clin
Gastroenterol Hepatol 2005; 3: 945–958.
9 Swinkels DW, Jorna AT, Raymakers RA: Synopsis of the Dutch multidisciplinary
guideline for the diagnosis and treatment of hereditary haemochromatosis. Neth J Med
2007; 65: 452–455.
10 Camaschella C, Poggiali E: Rare types of genetic hemochromatosis. Acta Haematol
2009; 122: 140–145.
11 Brissot P, Bardou-Jacquet E, Jouanolle AM, Loreal O: Iron disorders of genetic origin:
a changing world. Trends Mol Med 2011; 17: 707–713.
12 Aguilar-Martinez P, Grandchamp B, Cunat S et al: Iron overload in HFE C282Y
heterozygotes at ﬁrst genetic testing: a strategy for identifying rare HFE variants.
Haematologica 2011; 96: 507–514.
13 Le Gac G, Congiu R, Gourlaouen I, Cau M, Ferec C, Melis MA: Homozygous deletion of
HFE is the common cause of hemochromatosis in Sardinia. Haematologica 2010; 95:
685–687.
14 Lok CY, Merryweather-Clarke AT, Viprakasit V et al: Iron overload in the Asian
community. Blood 2009; 114: 20–25.
15 Hayashi H, Wakusawa S, Motonishi S et al: Genetic background of primary iron
overload syndromes in Japan. Intern Med 2006; 45: 1107–1111.
16 McDonald CJ, Wallace DF, Crawford DH, Subramaniam VN: Iron storage disease in
Asia-Paciﬁc populations: the importance of non-HFE mutations. J Gastroenterol
Hepatol 2013; 28: 1087–1094.
17 Kato J, Fujikawa K, Kanda M et al: A mutation, in the iron-responsive element of H
ferritin mRNA, causing autosomal dominant iron overload. Am J Hum Genet 2001;
69: 191–197.
18 Andriopoulos Jr B, Corradini E, Xia Y et al: BMP6 is a key endogenous regulator of
hepcidin expression and iron metabolism. Nat Genet 2009; 41: 482–487.
19 Vujic Spasic M, Sparla R, Mleczko-Sanecka K et al: Smad6 and Smad7 are co-
regulated with hepcidin in mouse models of iron overload. Biochim Biophys Acta
2013; 1832: 76–84.
20 Donker AE, Raymakers RA, Vlasveld LT et al: Practice guidelines for the diagnosis and
management of microcytic anemias due to genetic disorders of iron metabolism or
heme synthesis. Blood 2014; 123: 3873–3886, quiz 4005.
21 Camaschella C, Roetto A, De Gobbi M: Juvenile hemochromatosis. Semin Hematol
2002; 39: 242–248.
22 Bardou-Jacquet E, Cunat S, Beaumont-Epinette MP et al: Variable age of onset and
clinical severity in transferrin receptor 2 related haemochromatosis: novel observa-
tions. Br J Haematol 2013; 162: 278–281.
23 Camaschella C, Roetto A, Cali A et al: The gene TFR2 is mutated in a new type of
haemochromatosis mapping to 7q22. Nat Genet 2000; 25: 14–15.
24 Swinkels DW, Venselaar H, Wiegerinck ET et al: A novel (Leu183Pro-)mutation in the
HFE-gene co-inherited with the Cys282Tyr mutation in two unrelated Dutch
hemochromatosis patients. Blood Cells Mol Dis 2008; 40: 334–338.
25 Drakesmith H, Schimanski LM, Ormerod E et al: Resistance to hepcidin is conferred
by hemochromatosis-associated mutations of ferroportin. Blood 2005; 106:
1092–1097.
26 Deugnier Y, Turlin B: Pathology of hepatic iron overload. World J Gastroenterol 2007;
13: 4755–4760.
27 Adams PC: Hemochromatosis case deﬁnition: out of focus? Nat Clin Pract Gastro-
enterol Hepatol 2006; 3: 178–179.
28 European Association For The Study Of The Liver: EASLD clinical practice guidelines
for HFE hemochromatosis. J Hepatol 2010; 53: 3–22.
29 Porto G, Vicente C, Fraga J, da Silva BM, de Sousa M: Importance of establishing
appropriate local reference values for the screening of hemochromatosis: a study of
three different control populations and 136 hemochromatosis family members.
Hemochromatosis Clinical and Research Group. J Lab Clin Med 1992; 119:
295–305.
30 Adams PC, Speechley M, Barton JC, McLaren CE, McLaren GD, Eckfeldt JH:
Probability of C282Y homozygosity decreases as liver transaminase activities increase
in participants with hyperferritinemia in the hemochromatosis and iron overload
screening study. Hepatology 2012; 55: 1722–1726.
31 Adams PC, Barton JC: A diagnostic approach to hyperferritinemia with a non-elevated
transferrin saturation. J Hepatol 2011; 55: 453–458.
32 El-Serag HB, Inadomi JM, Kowdley KV: Screening for hereditary hemochromatosis in
siblings and children of affected patients. A cost-effectiveness analysis. Ann Intern
Med 2000; 132: 261–269.
Hereditary hemochromatosis guidelines
G Porto et al
492
European Journal of Human Genetics
33 Bulaj ZJ, Ajioka RS, Phillips JD et al: Disease-related conditions in relatives of
patients with hemochromatosis. N Engl J Med 2000; 343: 1529–1535.
34 Whitlock EP, Garlitz BA, Harris EL, Beil TL, Smith PR: Screening for hereditary
hemochromatosis: a systematic review for the U.S. Preventive Services Task Force.
Ann Intern Med 2006; 145: 209–223.
35 Grosse SD, Rogowski WH, Ross LF, Cornel MC, Dondorp WJ, Khoury MJ: Population
screening for genetic disorders in the 21st century: evidence, economics, and ethics.
Public Health Genomics 2010; 13: 106–115.
36 GRADE Working Group: http://www.gradeworkinggroup.org/index.htm.
37 EMQN Quality in the world of Molecular Genetics: http://www.cmgs.org/BPGs/
Best_Practice_Guidelines.htm.
38 Swiss Society of Medical Genetics: http://www.sgmg.ch/view_page_professional.php?
view=page&page_id=18.
39 Deutsche Gesellschaft für Humangenetik: http://www.gfhev.de/en/documents/index.
htm.
40 The European Molecular Genetics Quality Network: http://www.emqn.org.
41 Eurogentest: http://www.eurogentest.org/documents/.
42 Centre de référence des surcharges en fer rare d'origine génétique: http://www.centre-
reference-fer-rennes.org/.
43 Jouanolle AM, Gerolami V, Ged C et al: [Molecular diagnosis of HFE mutations in
routine laboratories. Results of a survey from reference laboratories in France]. Ann
Biol Clin 2012; 70: 305–313.
44 Haute Autorité de Santé: http://www.has-sante.fr/portail/upload/docs/application/pdf/
haemochromatosis_abstract.pdf.
45 British Committee for Standards in Haematology http://www.bcshguidelines.com/
documents/haemochromotosis_2000.pdf, 2000.
46 Leitlinien zur molekular genetischen Diagnostik der HH: http://www.gfhev.de/de/
leitlinien/LL_und_Stellungnahmen/ 2008-12-Haemochromatose.pdf, 2008.
47 King C, Barton DE: Best practice guidelines for the molecular genetic diagnosis of
Type 1 (HFE-related) hereditary haemochromatosis. BMC Med Genet 2006; 7: 81.
48 Feder JN, Gnirke A, Thomas W et al: A novel MHC class I-like gene is mutated in
patients with hereditary haemochromatosis. Nat Genet 1996; 13: 399–408.
49 Bacon BR, Olynyk JK, Brunt EM, Britton RS, Wolff RK: HFE genotype in patients
with hemochromatosis and other liver diseases. Ann Intern Med 1999; 130:
953–962.
50 Bauduer F, Scribans C, Degioanni A, Renoux M, Dutour O: Distribution of the C282Y
and H63D polymorphisms in hereditary hemochromatosis patients from the French
Basque Country. Ann Hematol 2005; 84: 99–102.
51 Bell H, Berg JP, Undlien DE et al: The clinical expression of hemochromatosis in Oslo,
Norway. Excessive oral iron intake may lead to secondary hemochromatosis even in
HFE C282Y mutation negative subjects. Scand J Gastroenterol 2000; 35:
1301–1307.
52 Beutler E, Gelbart T, West C et al: Mutation analysis in hereditary hemochromatosis.
Blood Cells Mol Dis 1996; 22: 187–194, discussion 194a–194b.
53 Borot N, Roth M, Malfroy L et al: Mutations in the MHC class I-like candidate gene for
hemochromatosis in French patients. Immunogenetics 1997; 45: 320–324.
54 Brandhagen DJ, Fairbanks VF, Baldus WP et al: Prevalence and clinical signiﬁcance of
HFE gene mutations in patients with iron overload. Am J Gastroenterol 2000; 95:
2910–2914.
55 Brissot P, Moirand R, Jouanolle AM et al: A genotypic study of 217 unrelated
probands diagnosed as "genetic hemochromatosis" on "classical" phenotypic criteria.
J Hepatol 1999; 30: 588–593.
56 Burt MJ, Upton JD, Morison IM, Chapman BA, Faed JM, George PM: Molecular
analysis of HLA-H gene mutations in New Zealand patients with haemochromatosis. N
Z Med J 1997; 110: 429–432.
57 Cardoso EM, Stal P, Hagen K et al: HFE mutations in patients with hereditary
haemochromatosis in Sweden. J Intern Med 1998; 243: 203–208.
58 Carella M, D'Ambrosio L, Totaro A et al: Mutation analysis of the HLA-H gene in Italian
hemochromatosis patients. Am J Hum Genet 1997; 60: 828–832.
59 Consortium U: A simple genetic test identiﬁes 90% of UK patients with
haemochromatosis. The UK Haemochromatosis Consortium. Gut 1997; 41:
841–844.
60 Datz C, Lalloz MR, Vogel W et al: Predominance of the HLA-H Cys282Tyr mutation in
Austrian patients with genetic haemochromatosis. J Hepatol 1997; 27: 773–779.
61 De JD, Reta A, Castiella A, Pozueta J, Prada A, Cuadrado E: HFE gene mutations
analysis in Basque hereditary haemochromatosis patients and controls. Eur J Hum
Genet 2001; 9: 961–964.
62 De Marco F, Liguori R, Giardina MG et al: High prevalence of non-HFE gene-
associated haemochromatosis in patients from southern Italy. Clin Chem Lab Med
2004; 42: 17–24.
63 Guix P, Picornell A, Parera M et al: Distribution of HFE C282Y and H63D mutations in
the Balearic Islands (NE Spain). Clin Genet 2002; 61: 43–48.
64 Hellerbrand C, Bosserhoff AK, Seegers S et al: Mutation analysis of the HFE gene in
German hemochromatosis patients and controls using automated SSCP-based
capillary electrophoresis and a new PCR-ELISA technique. Scand J Gastroenterol
2001; 36: 1211–1216.
65 Jazwinska EC, Cullen LM, Busﬁeld F et al: Haemochromatosis and HLA-H. Nat Genet
1996; 14: 249–251.
66 Jouanolle AM, Gandon G, Jezequel P et al: Haemochromatosis and HLA-H. Nat Genet
1996; 14: 251–252.
67 Moirand R, Jouanolle AM, Brissot P, Le Gall JY, David V, Deugnier Y: Phenotypic
expression of HFE mutations: a French study of 1110 unrelated iron-overloaded
patients and relatives. Gastroenterology 1999; 116: 372–377.
68 Mura C, Raguenes O, Ferec C: HFE mutations analysis in 711 hemochromatosis
probands: evidence for S65C implication in mild form of hemochromatosis. Blood
1999; 93: 2502–2505.
69 Murphy S, Curran MD, McDougall N, Callender ME, O'Brien CJ, Middleton D:
High incidence of the Cys 282 Tyr mutation in the HFE gene in the Irish
population–implications for haemochromatosis. Tissue Antigens 1998; 52:
484–488.
70 Nielsen P, Carpinteiro S, Fischer R, Cabeda JM, Porto G, Gabbe EE: Prevalence of the
C282Y and H63D mutations in the HFE gene in patients with hereditary haemochro-
matosis and in control subjects from Northern Germany. Br J Haematol 1998; 103:
842–845.
71 Piperno A, Sampietro M, Pietrangelo A et al: Heterogeneity of hemochromatosis
in Italy. Gastroenterology 1998; 114: 996–1002.
72 Rivard SR, Mura C, Simard H et al: Mutation analysis in the HFE gene in patients with
hereditary haemochromatosis in Saguenay-Lac-Saint-Jean (Quebec, Canada). Br J
Haematol 2000; 108: 854–858.
73 Ryan E, O'Keane C, Crowe J: Hemochromatosis in Ireland and HFE. Blood Cells Mol
Dis 1998; 24: 428–432.
74 Sanchez M, Bruguera M, Bosch J, Rodes J, Ballesta F, Oliva R: Prevalence of the
Cys282Tyr and His63Asp HFE gene mutations in Spanish patients with hereditary
hemochromatosis and in controls. J Hepatol 1998; 29: 725–728.
75 Sham RL, Ou CY, Cappuccio J, Braggins C, Dunnigan K, Phatak PD: Correlation
between genotype and phenotype in hereditary hemochromatosis: analysis of 61 cases.
Blood Cells Mol Dis 1997; 23: 314–320.
76 Sham RL, Raubertas RF, Braggins C, Cappuccio J, Gallagher M, Phatak PD:
Asymptomatic hemochromatosis subjects: genotypic and phenotypic proﬁles. Blood
2000; 96: 3707–3711.
77 Van Vlierberghe H, Messiaen L, Hautekeete M, De Paepe A, Elewaut A: Prevalence of
the Cys282Tyr and His63Asp mutation in Flemish patients with hereditary hemo-
chromatosis. Acta Gastroenterol Belg 2000; 63: 250–253.
78 Willis G, Jennings BA, Goodman E, Fellows IW, Wimperis JZ: A high prevalence of
HLA-H 845A mutations in hemochromatosis patients and the normal population in
eastern England. Blood Cells Mol Dis 1997; 23: 288–291.
79 Adams PC, Kertesz AE, McLaren CE, Barr R, Bamford A, Chakrabarti S: Population
screening for hemochromatosis: a comparison of unbound iron-binding capacity,
transferrin saturation, and C282Y genotyping in 5,211 voluntary blood donors.
Hepatology 2000; 31: 1160–1164.
80 Allen KJ, Gurrin LC, Constantine CC et al: Iron-overload-related disease in HFE
hereditary hemochromatosis. N Engl J Med 2008; 358: 221–230.
81 Altes A, Ruiz A, Barcelo MJ et al: Prevalence of the C282Y, H63D, and S65C
mutations of the HFE gene in 1,146 newborns from a region of Northern Spain. Genet
Test 2004; 8: 407–410.
82 Andrikovics H, Kalmar L, Bors A et al: Genotype screening for hereditary hemochro-
matosis among voluntary blood donors in Hungary. Blood Cells Mol Dis 2001; 27:
334–341.
83 Aranda N, Viteri FE, Fernandez-Ballart J, Murphy M, Arija V: Frequency of the
hemochromatosis gene (HFE) 282C–4Y, 63H–4D, and 65S–4C mutations in a
general Mediterranean population from Tarragona, Spain. Ann Hematol 2007; 86:
17–21.
84 Baiget M, Barcelo MJ, Gimferrer E: Frequency of the HFE C282Y and H63D
mutations in distinct ethnic groups living in Spain. J Med Genet 1998; 35: 701.
85 Barry E, Derhammer T, Elsea SH: Prevalence of three hereditary hemochromatosis
mutant alleles in the Michigan Caucasian population. Community Genet 2005; 8:
173–179.
86 Beutler E, Felitti V, Gelbart T, Ho N: The effect of HFE genotypes on measurements of
iron overload in patients attending a health appraisal clinic.[Erratum appears in Ann
Intern Med 2001;134(8):715]. Ann Intern Med 2000; 133: 329–337.
87 Beutler E, Felitti VJ, Koziol JA, Ho NJ, Gelbart T: Penetrance of 845G–4 A (C282Y)
HFE hereditary haemochromatosis mutation in the USA. Lancet 2002; 359:
211–218.
88 Burt MJ, George PM, Upton JD et al: The signiﬁcance of haemochromatosis gene
mutations in the general population: implications for screening. Gut 1998; 43:
830–836.
89 Byrnes V, Ryan E, Barrett S, Kenny P, Mayne P, Crowe J: Genetic hemochromatosis, a
Celtic disease: is it now time for population screening? Genet Test 2001; 5: 127–130.
90 Candore G, Mantovani V, Balistreri CR et al: Frequency of the HFE gene mutations in
ﬁve Italian populations. Blood Cells Mol Dis 2002; 29: 267–273.
91 Cimburova M, Putova I, Provaznikova H, Horak J: Hereditary hemochromatosis:
detection of C282Y and H63D mutations in HFE gene by means of guthrie cards in
population of Czech Republic. Genet Epidemiol 2002; 23: 260–263.
92 Cukjati M, Vaupotic T, Rupreht R, Curin-Serbec V: Prevalence of H63D, S65C
and C282Y hereditary hemochromatosis gene mutations in Slovenian
population by an improved high-throughput genotyping assay. BMC Med Genet
2007; 8: 69.
93 Distante S, Berg JP, Lande K, Haug E, Bell H: High prevalence of the
hemochromatosis-associated Cys282Tyr HFE gene mutation in a healthy Norwegian
population in the city of Oslo, and its phenotypic expression. Scand J Gastroenterol
1999; 34: 529–534.
94 Floreani A, Rosa RE, Basso D et al: An open population screening study for HFE gene
major mutations proves the low prevalence of C282Y mutation in Central Italy.
Aliment Pharmacol Ther 2007; 26: 577–586.
95 Guttridge MG, Carter K, Worwood M, Darke C: Population screening for hemochro-
matosis by PCR using sequence-speciﬁc primers. Genet Test 2000; 4: 111–114.
Hereditary hemochromatosis guidelines
G Porto et al
493
European Journal of Human Genetics
96 Hoppe C, Watson RM, Long CM et al: Prevalence of HFE mutations in California
newborns. Pediatr Hematol Oncol 2006; 23: 507–516.
97 Jackson HA, Carter K, Darke C et al: HFE mutations, iron deﬁciency and overload in
10,500 blood donors. Br J Haematol 2001; 114: 474–484.
98 Jones DC, Young NT, Pigott C et al: Comprehensive hereditary hemochromatosis
genotyping. Tissue Antigens 2002; 60: 481–488.
99 Kucinskas L, Juzenas S, Sventoraityte J et al: Prevalence of C282Y, H63D, and S65C
mutations in hereditary HFE-hemochromatosis gene in Lithuanian population. Ann
Hematol 2012; 91: 491–495.
100 Mariani R, Salvioni A, Corengia C et al: Prevalence of HFE mutations in upper
Northern Italy: study of 1132 unrelated blood donors. Dig Liver Dis 2003; 35:
479–481.
101 Marshall DS, Linfert DR, Tsongalis GJ: Prevalence of the C282Y and H63D
polymorphisms in a multi-ethnic control population. Int J Mol Med 1999; 4:
389–393.
102 Matas M, Guix P, Castro JA et al: Prevalence of HFE C282Y and H63D in Jewish
populations and clinical implications of H63D homozygosity. Clin Genet 2006; 69:
155–162.
103 McLaren GD, Gordeuk VR: Hereditary hemochromatosis: insights from the Hemo-
chromatosis and Iron Overload Screening (HEIRS) Study. Hematology Am Soc
Hematol Educ Program 2009; 195–206.
104 Meier P, Schuff-Werner P, Steiner M: Hemochromatosis gene HFE Cys282Tyr
mutation analysis in a cohort of Northeast German hospitalized patients supports
assumption of a North to South allele frequency gradient throughout Germany. Clin
Lab 2005; 51: 539–543.
105 Merryweather-Clarke AT, Pointon JJ, Shearman JD, Robson KJ: Global prevalence of
putative haemochromatosis mutations. J Med Genet 1997; 34: 275–278.
106 Merryweather-Clarke AT, Simonsen H, Shearman JD, Pointon JJ, Norgaard-Pedersen
B, Robson KJ: A retrospective anonymous pilot study in screening newborns for HFE
mutations in Scandinavian populations. Hum Mutat 1999; 13: 154–159.
107 Olynyk JK, Cullen DJ, Aquilia S, Rossi E, Summerville L, Powell LW: A population-
based study of the clinical expression of the hemochromatosis gene. N Engl J Med
1999; 341: 718–724.
108 Phatak PD, Ryan DH, Cappuccio J et al: Prevalence and penetrance of HFE
mutations in 4865 unselected primary care patients. Blood Cells Mol Dis 2002; 29:
41–47.
109 Pozzato G, Zorat F, Nascimben F et al: Haemochromatosis gene mutations in a
clustered Italian population: evidence of high prevalence in people of Celtic ancestry.
Eur J Hum Genet 2001; 9: 445–451.
110 Andersen RV, Tybjaerg-Hansen A, Appleyard M, Birgens H, Nordestgaard BG:
Hemochromatosis mutations in the general population: iron overload
progression rate. Blood 2004; 103: 2914–2919.
111 Gurrin LC, Bertalli NA, Dalton GW et al: HFE C282Y/H63D compound hetero-
zygotes are at low risk of hemochromatosis-related morbidity. Hepatology 2009; 50:
94–101.
112 Lim EM, Rossi E, De Boer WB, Reed WD, Jeffrey GP: Hepatic iron loading in patients
with compound heterozygous HFE mutations. Liver Int 2004; 24: 631–636.
113 Ramakrishna R, Gupta S, Sarathy K, Bowen A: Phenotypic and clinical manifestations
of compound heterozygous genetic haemochromatosis (CHGH): a non-invasive
approach to clinical management. Intern Med J 2013; 43: 254–261.
114 Walsh A, Dixon JL, Ramm GA et al: The clinical relevance of compound heterozygosity
for the C282Y and H63D substitutions in hemochromatosis. Clin Gastroenterol
Hepatol 2006; 4: 1403–1410.
115 Bajaj J, Knox JF, Komorowski R, Saeian K: The irony of herbal hepatitis: Ma-Huang-
induced hepatotoxicity associated with compound heterozygosity for hereditary
hemochromatosis. Dig Dis Sci 2003; 48: 1925–1928.
116 Schoniger-Hekele M, Muller C, Polli C, Wrba F, Penner E, Ferenci P: Liver pathology
in compound heterozygous patients for hemochromatosis mutations. Liver 2002; 22:
295–301.
117 Cheng R, Barton JC, Morrison ED et al: Differences in hepatic phenotype between
hemochromatosis patients with HFE C282Y homozygosity and other HFE genotypes. J
Clin Gastroenterol 2009; 43: 569–573.
118 Neghina AM, Anghel A: Hemochromatosis genotypes and risk of iron overload–a meta-
analysis. Ann Epidemiol 2011; 21: 1–14.
119 Kelley M, Joshi N, Xie Y, Borgaonkar M: Iron overload is rare in patients homozygous
for the H63D mutation. Can J Gastroenterol Hepatol 2014; 28: 198–202.
120 Aguilar-Martinez P, Bismuth M, Picot MC et al: Variable phenotypic presentation of
iron overload in H63D homozygotes: are genetic modiﬁers the cause? Gut 2001; 48:
836–842.
121 Krawczak M: ASP–a simulation-based power calculator for genetic linkage studies of
qualitative traits, using sib-pairs. Hum Genet 2001; 109: 675–677.
122 Jacobs EM, Hendriks JC, Marx JJ et al: Morbidity and mortality in ﬁrst-degree relatives
of C282Y homozygous probands with clinically detected haemochromatosis compared
with the general population: the HEmochromatosis FAmily Study (HEFAS). Neth J
Med 2007; 65: 425–433.
123 Powell LW, Dixon JL, Ramm GA et al: Screening for hemochromatosis in asympto-
matic subjects with or without a family history. Arch Intern Med 2006; 166:
294–301.
124 McCune CA, Ravine D, Carter K et al: Iron loading and morbidity among relatives of
HFE C282Y homozygotes identiﬁed either by population genetic testing or presenting
as patients. Gut 2006; 55: 554–562.
125 Lazarescu A, Snively BM, Adams PC: Phenotype variation in C282Y homozygotes for
the hemochromatosis gene. Clin Gastroenterol Hepatol 2005; 3: 1043–1046.
126 Jacobs EM HJ, van Deursen CT, Kreeftenberg HG, de Vries RA, Marx JJ, Stalenhoef
AF VA, Swinkels DW: Severity of iron overload of proband determines serum ferritin
levels in families with HFE-related hemochromatosis: the HEmochromatosis
FAmily Study. J Hepatol 2009; 50: 174–183.
127 Gleeson FRE, Barrett S, Crowe J: Clinical expression of haemochromatosis in Irish
C282Y homozygotes identiﬁed through family screening. Eur J Gastroenterol Hepatol
2004; 16: 859–63.
128 Powell LW: Diagnosis of hemochromatosis. Semin Gastrointest Dis 2002; 13: 80–88.
129 Elmberg M, Hultcrantz R, Simard JF, Carlsson A, Askling J: Increased risk of
arthropathies and joint replacement surgery in patients with genetic hemochroma-
tosis: a study of 3,531 patients and their 11,794 ﬁrst-degree relatives. Arthritis Care
Res 2013; 65: 678–685.
130 Nelson RL PV, Davis F, Becker E: Risk of disease in siblings of patients with
hereditary hemochromatosis. Digestion 2001; 64: 120–124.
131 Elmberg M, Hultcrantz R, Ebrahim F et al: Increased mortality risk in patients with
phenotypic hereditary hemochromatosis but not in their ﬁrst-degree relatives.
Gastroenterology 2009; 137: 1301–1309.
132 Adams P: Hemochromatosis: new insights in pathogenesis and diagnosis following the
discovery of the gene. Crit Rev Clin Lab Sci 1998; 35: 239–273.
133 Independent UK Panel on Breast Cancer Screening: The beneﬁts and harms of breast
cancer screening:an independent review. Lancet 2012; 380: 1778–1786.
134 McPherson K: Screening for breast cancer - balancing the debate. BMJ 2010; 340:
c3106.
135 Beral V, Alexander M, Duffy S et al. The number of women who would need to be
screened regularly by mammography to prevent one death from breast cancer. J Med
Screen 2011; 18: 210–212.
136 Reyes M, Dunet DO, Isenberg KB, Trisolini M, Wagener DK: Family-based detection
for hereditary hemochromatosis. J Genet Couns 2008; 17: 92–100.
137 Aleman S, Endalib S, Stal P et al: Health check-ups and family screening allow
detection of hereditary hemochromatosis with less advanced liver ﬁbrosis and survival
comparable with the general population. Scand J Gastroenterol 2011; 46:
1118–1126.
138 Beaton MD, Adams PC: Prognostic factors and survival in patients with hereditary
hemochromatosis and cirrhosis. Can J Gastroenterol 2006; 20: 257–260.
139 Niederau C, Fischer R, Purschel A, Stremmel W, Haussinger D, Strohmeyer G: Long-
term survival in patients with hereditary hemochromatosis. Gastroenterology 1996;
110: 1107–1119.
140 Bardou-Jacquet EMF, Perrin M, Manet G, Guyader D, Moirand R, Deugnier Y: Survival
and Causes of Death in a cohort of 1086 treated C282Y HFE Homozygous Patients.
Am J Hematol 2013; 88: E38.
141 Asberg A, Hveem K, Kannelonning K, Irgens WO: Penetrance of the C28Y/C282Y
genotype of the HFE gene. Scand J Gastroenterol 2007; 42: 1073–1077.
142 Waalen J, Felitti V, Gelbart T, Ho NJ, Beutler E: Prevalence of hemochromatosis-
related symptoms among individuals with mutations in the HFE gene. Mayo Clin Proc
2002; 77: 522–530.
143 Deugnier Y, Jouanolle AM, Chaperon J et al: Gender-speciﬁc phenotypic expression
and screening strategies in C282Y-linked haemochromatosis: a study of 9396
French people. Br J Haematol 2002; 118: 1170–1178.
144 Adams PC, Passmore L, Chakrabarti S et al: Liver diseases in the hemochromatosis
and iron overload screening study. Clin Gastroenterol Hepatol 2006; 4:
918–923, quiz 807.
145 Gordeuk VR, Reboussin DM, McLaren CE et al: Serum ferritin concentrations and
body iron stores in a multicenter, multiethnic primary-care population. Am J Hematol
2008; 83: 618–626.
146 Aranda N, Viteri FE, Montserrat C, Arija V: Effects of C282Y, H63D, and S65C HFE
gene mutations, diet, and life-style factors on iron status in a general Mediterranean
population from Tarragona, Spain. Ann Hematol 2010; 89: 767–773.
147 Burke W, Imperatore G, McDonnell SM, Baron RC, Khoury MJ: Contribution of
different HFE genotypes to iron overload disease: a pooled analysis. Genet Med 2000;
2: 271–277.
148 Waalen J, Felitti VJ, Gelbart T, Beutler E: Screening for hemochromatosis by measuring
ferritin levels: a more effective approach. Blood 2008; 111: 3373–3376.
149 Adams PC: The natural history of untreated HFE-related hemochromatosis. Acta
Haematol 2009; 122: 134–139.
150 Van Aken MO, De Craen AJ, Gussekloo J et al: No increase in mortality and
morbidity among carriers of the C282Y mutation of the hereditary haemochromatosis
gene in the oldest old: the Leiden 85-plus study. Eur J Clin Invest 2002; 32:
750–754.
151 Njajou OT, Houwing-Duistermaat JJ, Osborne RH et al: A population-based study of
the effect of the HFE C282Y and H63D mutations on iron metabolism. Eur J Hum
Genet 2003; 11: 225–231.
152 Rossi E, Bulsara MK, Olynyk JK, Cullen DJ, Summerville L, Powell LW: Effect of
hemochromatosis genotype and lifestyle factors on iron and red cell indices in a
community population. Clin Chem 2001; 47: 202–208.
153 Schiepers OJ, van Boxtel MP, de Groot RH et al: Serum iron parameters, HFE C282Y
genotype, and cognitive performance in older adults: results from the FACIT study. J
Gerontol A Biol Sci Med Sci 2010; 65: 1312–1321.
154 Olynyk JK, Hagan SE, Cullen DJ, Beilby J, Whittall DE: Evolution of untreated
hereditary hemochromatosis in the Busselton population: a 17-year study. Mayo Clin
Proc 2004; 79: 309–313.
155 Yamashita C, Adams PC: Natural history of the C282Y homozygote for the
hemochromatosis gene (HFE) with a normal serum ferritin level. Clin Gastroenterol
Hepatol 2003; 1: 388–391.
Hereditary hemochromatosis guidelines
G Porto et al
494
European Journal of Human Genetics
156 Gurrin LC, Osborne NJ, Constantine CC et al: The natural history of serum iron indices
for HFE C282Y homozygosity associated with hereditary hemochromatosis. Gastro-
enterology 2008; 135: 1945–1952.
157 Allen KJ, Bertalli NA, Osborne NJ et al: HFE Cys282Tyr homozygotes with serum
ferritin concentrations below 1000 microg/L are at low risk of hemochromatosis.
Hepatology 2010; 52: 925–933.
158 Von Recklinghausen F Ueber Haemochromatose. Naturforscher Arzte Heidelberg:
Tageblatt Versammlung Dische, 1989.
159 Sheldon J: Haemochromatosis. Oxford University Press: London: London, 1935.
160 Simon M, Bourel M, Genetet B, Fauchet R: Idiopathic hemochromatosis. Demonstra-
tion of recessive transmission and early detection by family HLA typing. N Engl J Med
1977; 297: 1017–1021.
161 Schimanski LM, Drakesmith H, Merryweather-Clarke AT et al: In vitro functional
analysis of human ferroportin (FPN) and hemochromatosis-associated FPN mutations.
Blood 2005; 105: 4096–4102.
162 Montosi G, Donovan A, Totaro A et al: Autosomal-dominant hemochromatosis is
associated with a mutation in the ferroportin (SLC11A3) gene. J Clin Invest 2001;
108: 619–623.
163 Ellervik C, Birgens H, Tybjaerg-Hansen A, Nordestgaard BG: Hemochromatosis
genotypes and risk of 31 disease endpoints: meta-analyses including 66,000 cases
and 226,000 controls. Hepatology 2007; 46: 1071–1080.
164 Pedersen P, Melsen GV, Milman N: Frequencies of the haemochromatosis gene (HFE)
variants C282Y, H63D and S65C in 6,020 ethnic Danish men. Ann Hematol 2008;
87: 735–740.
165 Pedersen P, Milman N: Extrinsic factors modifying expressivity of the HFE variant C282Y,
H63D, S65C phenotypes in 1,294 Danish men. Ann Hematol 2009; 88: 957–965.
166 Ellard S, Lindsay H, Camm N et al. Practice guidelines for Targeted Next Generation
Sequencing Analysis and Interpretation. 2012. http://www.acgs.uk.com/.
167 Teixeira E, Borlido-Santos J, Brissot P et al: The importance of the general practitioner
as an information source for patients with hereditary haemochromatosis. Patient Educ
Couns 2014; 96: 86–92.
168 Holmstrom P, Marmur J, Eggertsen G, Gafvels M, Stal P: Mild iron overload in patients
carrying the HFE S65C gene mutation: a retrospective study in patients with
suspected iron overload and healthy controls. Gut 2002; 51: 723–730.
169 International Organization for Standardization www.iso.org/iso/home.html.
170 Berwouts S, Morris MA, Dequeker E: Approaches to quality management and
accreditation in a genetic testing laboratory. Eur J Hum Genet 2010; 18: S1–19.
171 Bacon BR, Adams PC, Kowdley KV, Powell LW, Tavill AS: American Association for
the Study of Liver D: Diagnosis and management of hemochromatosis: 2011 practice
guideline by the American Association for the Study of Liver Diseases. Hepatology
2011; 54: 328–343.
172 Human Genome Variation Society: http://www.hgvs.org/rec.html.
173 Practice guidelines for the Interpretation and Reporting of Unclassiﬁed Variants (UVs)
in Clinical Molecular Genetics: http://cmgsweb.shared.hosting.zen.co.uk/BPGs/pdfs%
20current%20bpgs/UV%20GUIDELINES%20ratiﬁed.pdf.
174 The Human Gene Mutation Database: http://www.hgmd.cf.ac.uk/ac/index.php.
175 OECD Guidelines for Quality Assurance in Molecular Genetic Testing. http://www.
oecd.org/science/biotech/38839788.pdf.
176 Mutalyser: https:/mutalyser.nl.
This work is licensed under a Creative Commons
Attribution-NonCommercial-NoDerivs 4.0 International
License. The images or other third party material in this article are
included in the article’s Creative Commons license, unless indicated
otherwise in the credit line; if the material is not included under the
CreativeCommons license,userswillneed toobtainpermission fromthe
license holder to reproduce the material. To view a copy of this license,
visit http://creativecommons.org/licenses/by-nc-nd/4.0/
Supplementary Information accompanies this paper on European Journal of Human Genetics website (http://www.nature.com/ejhg)
Hereditary hemochromatosis guidelines
G Porto et al
495
European Journal of Human Genetics
